Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks

Aryl-aniline and heteroaryl-aniline compounds provide a localized treatment for birthmarks by targeting the ERK/MEK pathway, effectively suppressing p-ERK expression with reduced systemic side effects compared to existing MEK inhibitors.

CA3120336CActive Publication Date: 2026-11-03NFLECTION THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CA3120336
Authority / Receiving Office
CA · CA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-11-20
Filing Date
2019-11-20
Publication Date
2026-11-03
Estimated Expiration
2039-11-20

AI Technical Summary

Technical Problem

Current MEK pathway inhibitors for treating birthmarks have significant side effects and are not suitable for localized treatment, necessitating the development of therapies that effectively target birthmarks while minimizing systemic exposure-related adverse reactions.

Method used

Topical administration of aryl-aniline and heteroaryl-aniline compounds, specifically formulated in gel or other suitable delivery systems, to target the ERK/MEK pathway in birthmarks, providing localized treatment with reduced systemic side effects.

Benefits of technology

The compounds effectively suppress p-ERK expression in birthmarks, demonstrating therapeutic efficacy with minimal systemic side effects, thus offering a safer and more targeted treatment option.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to formula (IV): [Image disponible dans le document PDF, Image available in the PDF document]
Need to check novelty before this filing date? Find Prior Art

Description

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application claims priorty to U. S. Provisional Application No. 62 / 769,844, filed November 20, 2018. BACKGROUND OF THE INVENTION

[0002] Benign cutaneous tumors of the vascular, keratinocytic, and melanocytic compartments often occur at birth or during childhood. These lesions, referred in this application as "birthmarks", can cause cosmetic distress, disfigurement and social anxiety. In some cases, these lesions can predispose individuals to functional impairment or future malignancies. These birthmarks can be sporadic or arise as part of an underlying neurocutaneous syndrome.

[0003] Vascular birthmarks include, for example port wine stain / capillary malformation, angiomas, lobular capillary hemangiomas, arteriovascular malformation, lymphatic malformation, vascular malformation, hemangiomas, and other angioma. Keratinocytic nevi refers to Keratinocytic epidermal nevi and nevi sebacei. Melanocytic nevi (commonly known as moles) include, for example congenital nevi, multiple lentigines (which can occur in syndromes such as LEOPARD), ephiledes (freckles), and nevus spiilus.

[0004] Neurocutaneous syndromes, also referred to as birthmarks, such as port-wine stains, are associated with congenital low-flow vascular malformations (capillary malformation) in the skin which, if left untreated, can hypertrophy and develop nodularity (Minkis, K. et al, Lasers Surg Med. (2009) 41(6): pp423-426). Laser therapy is typically used for treatment of port-wine stains, but often without full resolution. Epidermal nevi are common cutaneous mosaic disorders, subdivided into keratinocytic and organoid nevi. Organoid nevi include nevus sebaceus (NS). Immunolabelling of NS is reportedly associated with increased phosphorylated ERK staining (Aslam, A, et al., Clinical and Experimental Dermatology (2014) 39: pp 1-6). Non-organoid keratinocytic epidermal nevus (KEN) is characterized by benign congenital hyperpigmented skin lesions. Epidermal nevi with localized epidermal thickening are present at birth or become visible during childhood. Other cutaneous disorders that also occur in childhood birthmarks include nevus cellular nevus, lobulary capillary hemangioma, congenital nevi, ephiledes (freckles), multiple lentigines (which can occur in multiple syndromes including LEOPARD syndrome), capillary angioma, nevus spilus, arterio-venous malformations, lymphatic malformations, and congenital melanocytic nevus. Lentigines can occur in childhood (in syndromes such as LEOPARD syndrome), which has mutations that activate RAS / MAPK pathway, as well as can be acquired in adults. In some cases birthmarks are not amenable to surgical excision and / or laser treatment. In some cases birthmarks, when untreated, can progress to lesions and / or proliferative skin conditions.

[0005] Modulation of ERK / MEK pathways may have a therapeutic effect on birthmarks. RAS mutations have been reported in mosaic RASopathies i.e. non-organoid KEN, and sebaceous nevus (Farschtschi S, et al., BMC Medical Genetics. (2015);16: pp 6; and Sun, B.K. et. Al, Journal of Investigative Dermatology, (2013); 3: pp824-827). Thus, inhibition of Ras signaling pathway, including the Ras-MAPK cascade, may be useful in treating birthmarks.

[0006] Four distinct MAPK cascades have been identified and named according to their MAPK module. See Akinleye et al. Journal of Hematology & Oncology 6:27, 2013. MEK proteins belong to a family of enzymes that lie upstream to their specific MAPK targets in each of the four MAP kinase signaling pathways. Two of these MEK proteins, MEK1 and MEK2, are closely related and participate in this signaling pathway cascade. Inhibitors of MEK1 and MEK2 have been shown to effectively inhibit MEK signaling downstream of Ras (Rice et al. Medicinal Chemistry Letters 3:416-421, 2012), and thus provide a rationale for targeting MEK in the treatment of birthmarks.

[0007] Currently available MEK pathway inhibitors are designed to have oral bioavailability for systemic delivery, but are associated with one or more significant side effects including decreased left ventricular ejection fraction, elevated creatine phosphokinase, pneumonitis, renal failure, diarrhea, infection, uticaria, and maculo-papular rash, all of which are dose limiting or require permanent discontinuation. Moreover, clinical trials have shown one or more side effects with prolonged high-dose administration of MEK inhibitors. (Huang et al. J. Ocul. Pharmacol. Ther. 25:519-530, 2009). For example, PD0325901, a clinically-tested MEK inhibitor, has exhibited one or more neurological side effects associated with ataxia, confusion, and syncope. In addition, a number of other side effects have been observed with systemic exposure to MEK inhibitors including: acneiform rash, CPK elevation, nausea, vomiting, diarrhea, abdominal pain, and fatigue. Thus, there is a need for therapies that treat birthmarks and also limit one or more side effects associated with systemic exposure to MEK / ERK pathway inhibitors. BRIEF SUMMARY OF THE INVENTION

[8000] In one aspect, provided herein is a method of treating a birthmark. The method includes administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of formula (I), (II), (III), (IV), and (V): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (I), [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (III), (IV), and [Image disponible dans le document PDF, Image available in the PDF document] or a N-oxide, stereoisomer, mixture of stereoisomers, and / or a pharmaceutically acceptable salt thereof, wherein: <com:Math><semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−CR13b<annotation encoding="application / x-tex">-CR^{13b}< / annotation>< / semantics>< / com:Math> or N; <com:Math><semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; <com:Math><semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics>< / com:Math> is S or O; subscript n is an integer from 0 to 2; bond "a" is a single or double bond; R<com:Sup>1< / com:Sup> is -OR<com:Sup>4< / com:Sup>, -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup>, -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup>, or a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>; <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is halo, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, -S-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math> cycloalkyl, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkenyl, or <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkynyl; <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is halo or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; R<com:Sup>4< / com:Sup>, R<com:Sup>5< / com:Sup>, and R<com:Sup>5b< / com:Sup> are each independently hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R5a<annotation encoding="application / x-tex">R^{5a}< / annotation>< / semantics>< / com:Math> is hydrogen or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, oxo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy, amino, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkylamino, di-<com:Math><semantics>(C1<annotation encoding="application / x-tex">(C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl)amino, hydroxyamino, or <com:Math><semantics>N−C1−C6<annotation encoding="application / x-tex">N-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl hydroxyamino; R<com:Sup>13< / com:Sup>, R<com:Sup>13a< / com:Sup>, and R<com:Sup>13b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl; R<com:Sup>23< / com:Sup>, R<com:Sup>23a< / com:Sup>, and R<com:Sup>23b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, or C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkoxy; R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy, or <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math> cycloalkoxy; <com:Math><semantics>R43<annotation encoding="application / x-tex">R^{43}< / annotation>< / semantics>< / com:Math> is cyano, <com:Math><semantics>−C(O)NR48R48a<annotation encoding="application / x-tex">-C(O)NR^{48}R^{48a}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(O)R46<annotation encoding="application / x-tex">-C(O)R^{46}< / annotation>< / semantics>< / com:Math>; R<com:Sup>43a< / com:Sup> is hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; or R<com:Sup>43< / com:Sup> and R<com:Sup>43a< / com:Sup> together form -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)- or -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)-, each of which is unsubstituted or substituted with one or two R<com:Sup>49< / com:Sup>; R<com:Sup>46< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl or heterocycloalkyl; R<com:Sup>48< / com:Sup> and R<com:Sup>48a< / com:Sup> are independently hydrogen or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each R<com:Sup>49< / com:Sup> is independently C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, or C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; R<com:Sup>51< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or -OR<com:Sup>54< / com:Sup>, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup>; each <com:Math><semantics>R53<annotation encoding="application / x-tex">R^{53}< / annotation>< / semantics>< / com:Math> is independently halo or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; R<com:Sup>53a< / com:Sup> and R<com:Sup>53b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl; and R<com:Sup>54< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino- C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to <com:Math><semantics>sixR6<annotation encoding="application / x-tex">six R^6< / annotation>< / semantics>< / com:Math>. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] FIG. 1 shows suppression of p-ERK in human epidermal nevus explants after application of topical formulations containing vehicle only, Compound 2.003 or Compound 4.013, using the protocol described in Example 1. FIG. 1A: untreated; FIG. 1B: vehicle only; FIG. 1C: Compound 2.003; and FIG. 1D: Compound 4.013.

[0010] FIG. 2 shows foci of hyperproliferation overlapping with p-ERK expression by Ki-67 staining of epidermal nevus, using the protocol described in Example 1.

[0011] FIGs. 3 and 4 shows suppression of p-ERK in human nevus sebaceous explants after application of gel topical formulations containing vehicle only, Trametinib, Compound 2.003, Compound 4.029, using the protocol described in Example 1.

[0012] FIG. 5 shows suppression of p-ERK in human nevus sebaceous explants after application of gel topical formulations containing vehicle only and Compound 2.003, using the protocol described in Example 1.

[0013] FIG. 6 shows a dose response of Compound 2.003 in suppression of p-ERK in human nevus sebaceous explants after application of gel topical formulations containing vehicle only and Compound 2.003, using the protocol described in Example 1.

[0014] FIGs. 7 and 8 show synthesis Scheme I-1 and Scheme I-2 for the preparation of a compound of formula (Ia), respectively.

[0015] FIG. 9 shows synthesis Scheme 1-3 for the preparation of a compound of formula (Ib).

[0016] FIGs. 10-14 show synthesies Schemes II-1 to II-5 for the preparation of a compound of formula (II), respectively.

[0017] FIGs. 15-16 show synthesis Schemes III-1 and III-2 for the preparation of a compound of formula (IIIa), respectively.

[0018] FIG. 17 shows synthesis Scheme IV-1 for the preparation of a compound of any one of formulae (IVa), (IVb), and (IVc).

[0019] FIG. 18 shows synthesis Scheme IV-2 for the preparation of a compound of any one of formulae (IVd-1), (IVd-2), (IVe-1) and (IVe-2).

[0020] FIG. 19 shows synthesis Scheme IV-3 for the preparation of a compound of formula (IVa).

[0021] FIGs. 20-21 show synthesis Scheme V-1 and V-2 for the preparation of a compound of formula (Va), repectively.

[0022] FIG. 22 shows synthesis Scheme V-3 for the preparation of a compound of formula (Vb). DETAILED DESCRIPTION OF THE INVENTION I. GENERAL

[0023] Provided herein are methods of using compounds and pharmaceutical compositions comprising the compounds for treating birthmarks.

[0024] The birthmarks of the present invention are as defined and described as follows:

[0025] In some embodiments, the birthmark is a port-wine stain (capillary malformation). Port-wine stains may be present at birth. Port-wine stains can occur anywhere on the body and the area of affected skin grows in proportion to general growth. Thickening of the lesion or the development of small lumps may occur in adulthood and can interfere with normal function (e.g., where the port-wine stain is near the eye or mouth). Port-wine stains may, in some cases, be part of a syndrome such as Sturge-Weber syndrome or Klippel-Trénaunay-Weber syndrome.

[0026] In some embodiments, the birthmark is epidermal nevi. Epidermal nevus is a benign skin growth with localized epidermal thickening that is often present at birth or within the first year of life. It typically appears as one or more oblong or linear growths that are skin colored, brown or gray in color. The surface can be wart-like or velvety with sharp borders. Malignant transformation can occur in some cases in middle aged or elderly subjects. Epidermal nevi are subdivided into keratinocytic and organoid nevi. Organoid nevi include nevus sebaceous (NS). In some embodiments, the birthmark is nevus sebaceous. Non-organoid keratinocytic epidermal nevus (KEN) is characterized by benign congenital hyperpigmented skin lesions. Contemplated within the scope of embodiments presented herein are other types of epidermal nevi, including nevus comedonicus. Nevus comedonicus (NC) is a hamartoma of the pilosebaceous unit that, like other epidermal nevi, typically presents at birth or during childhood. Clinically, NC lesions consist of linear arrays or clusters of dilated, keratin-plugged follicular orifices resembling comedones.

[0027] In some embodiments the birthmark is melanocytic nevus, including congenital nevi, blue nevi, and acquired melanocytic nevi. Malignant melanoma occasionally develops from the melanocytic nevus (also known as nevocytic nevus, nevus-cell nevus and commonly as a mole). Reasons for treatment of pigmented nevi (i.e., nevus cellular nevus) include prevention of malignant change, limiting malignant progression, cosmetic improvement, or prevention of other functional or anatomical changes.

[0028] In some embodiments, the birthmark is dysplastic nevi. Dysplastic nevi (or atypical moles) are unusual-looking benign moles and may resemble melanoma. People who have atypical moles are at increased risk of developing melanoma in a mole or elsewhere on the body.

[0029] In some embodiments, the birthmark is a nevus spilus. Nevus spilus (also known as speckled lentiginous nevus and zosteriform lentiginous nevus) is a skin lesion that presents as a light brown patch of pigmentation, and within this patch, are multiple tiny dark brown spots.

[0030] In some embodiments, the birthmark is an arterio-venous malformation in the skin (e.g., blue rubber bleb nevus syndrome) which may present as skin lesions comprised of compressible blue subcutaneous nodules.

[0031] In some embodiments, the birthmark is a lymphatic malformation. A lymphatic malformation is a type of vascular nevus or birthmark due to malformed and dilated lymphatic vessels. The cystic hygroma (also called 'cystic lymphangioma' and 'lymphangioma cysticum') is a 'macrocytic' lymphatic malformation, and is composed of large fluid-filled spaces. It appears as a skin colored, red or bluish, somewhat transparent, swelling under the skin. Cavernous lymphangioma can affect any site on the body, including the tongue. Lymphangioma circumscriptum is a 'microcytic' lymphatic malformation. It appears as a cluster of small firm blisters filled with lymph fluid, resembling frogspawn.

[0032] In some embodiments, the birthmark is a congenital melanocytic nevus. The congenital melanocytic nevus appears as a circumscribed, light brown to black patch or plaque, heterogeneous in consistency, covering any size surface area and any part of the body. Congenital melanocytic nevus poses a risk for malignancy degeneration.

[0033] As used herein, the term 'birthmark' does not include cafe au lait spots. II. DEFINITION

[0034] The abbreviations used herein have their conventional meaning within the chemical and biological arts.

[0035] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the substituents that would result from writing the structure from right to left, e.g., -CH<com:Sub>2< / com:Sub>O- is meant to include -OCH<com:Sub>2< / com:Sub>-.

[0036] "Alkyl" refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated (i.e., C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> means one to six carbons). Alkyl can include any number of carbons, such as <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C7<annotation encoding="application / x-tex">C_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C9<annotation encoding="application / x-tex">C_9< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C10<annotation encoding="application / x-tex">C_{10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>- <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>. For example, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc. Alkyl can also refer to alkyl groups having up to 20 carbons atoms, such as, but not limited to heptyl, octyl, nonyl, decyl, etc.

[0037] "Alkylene" refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated (i.e., C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> means one to six carbons), and linking at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkylene can be linked to the same atom or different atoms of the alkylene group. For instance, a straight chain alkylene can be the bivalent radical of <com:Math><semantics>−(CH2)n−1<annotation encoding="application / x-tex">-(CH_2)_{n-1}< / annotation>< / semantics>< / com:Math>, where n is 1, 2, 3, 4, 5 or 6. Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene and hexylene.

[0038] "Alkenyl" refers to a straight chain or branched hydrocarbon having at least 2 carbon atoms and at least one double bond and having the number of carbon atom indicated (i.e., C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> means to two to six carbons). Alkenyl can include any number of carbons, such as <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C4<annotation encoding="application / x-tex">C_2-C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C5<annotation encoding="application / x-tex">C_2-C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C6<annotation encoding="application / x-tex">C_2-C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C7<annotation encoding="application / x-tex">C_2-C_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C8<annotation encoding="application / x-tex">C_2-C_8< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C9<annotation encoding="application / x-tex">C_2-C_9< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C10<annotation encoding="application / x-tex">C_2-C_{10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3−C4<annotation encoding="application / x-tex">C_3-C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3−C5<annotation encoding="application / x-tex">C_3-C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3−C6<annotation encoding="application / x-tex">C_3-C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4−C5<annotation encoding="application / x-tex">C_4-C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4−C5<annotation encoding="application / x-tex">C_4-C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, C<com:Sub>5< / com:Sub>-C<com:Sub>6< / com:Sub>, and C<com:Sub>6< / com:Sub>. Alkenyl groups can have any suitable number of double bonds, including, but not limited to, 1, 2, 3, 4, 5 or more. Examples of alkenyl groups include, but are not limited to, vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl.

[0039] "Alkynyl" refers to either a straight chain or branched hydrocarbon having at least 2 carbon atoms and at least one triple bond and having the number of carbon atom indicated (i.e., <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> means to two to six carbons). Alkynyl can include any number of carbons, such as <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C3<annotation encoding="application / x-tex">C_2-C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C4<annotation encoding="application / x-tex">C_2-C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C5<annotation encoding="application / x-tex">C_2-C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C6<annotation encoding="application / x-tex">C_2-C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C7<annotation encoding="application / x-tex">C_2-C_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C8<annotation encoding="application / x-tex">C_2-C_8< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C9<annotation encoding="application / x-tex">C_2-C_9< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2−C10<annotation encoding="application / x-tex">C_2-C_{10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3−C4<annotation encoding="application / x-tex">C_3-C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3−C5<annotation encoding="application / x-tex">C_3-C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3−C6<annotation encoding="application / x-tex">C_3-C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4−C5<annotation encoding="application / x-tex">C_4-C_5< / annotation>< / semantics>< / com:Math>, C<com:Sub>4< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>5< / com:Sub>, C<com:Sub>5< / com:Sub>-C<com:Sub>6< / com:Sub>, and C<com:Sub>6< / com:Sub>. Examples of alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatriynyl.

[0040] "Cycloalkyl" refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated. Cycloalkyl can include any number of carbons, such as C<com:Sub>3< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>4< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>5< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub>, C<com:Sub>4< / com:Sub>-C<com:Sub>8< / com:Sub>, C<com:Sub>5< / com:Sub>-C<com:Sub>8< / com:Sub>, C<com:Sub>6< / com:Sub>-C<com:Sub>8< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>9< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>10< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>11< / com:Sub>, and C<com:Sub>3< / com:Sub>-C<com:Sub>12< / com:Sub>. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2] bicyclooctane, decahydronaphthalene and adamantane. Cycloalkyl groups can also be partially unsaturated, having one or more double or triple bonds in the ring. Representative cycloalkyl groups that are partially unsaturated include, but are not limited to, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene (1,3- and 1,4-isomers), cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene (1,3-, 1,4- and 1,5-isomers), norbornene, and norbornadiene. When cycloalkyl is a saturated monocyclic C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, exemplary groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

[0041] "Cycloalkylalkyl" refers to a radical having an alkyl component and a cycloalkyl component, where the alkyl component links the cycloalkyl component to the point of attachment. The alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the cycloalkyl component and to the point of attachment. The alkyl component can include any number of carbons, such as C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>1< / com:Sub>-C<com:Sub>2< / com:Sub>, C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub>, C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>, C<com:Sub>1< / com:Sub>-C<com:Sub>5< / com:Sub>, C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub>, C<com:Sub>2< / com:Sub>-C<com:Sub>4< / com:Sub>, C<com:Sub>2< / com:Sub>-C<com:Sub>5< / com:Sub>, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>4< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>5< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>4< / com:Sub>-C<com:Sub>5< / com:Sub>, C<com:Sub>4< / com:Sub>-C<com:Sub>6< / com:Sub> and C<com:Sub>5< / com:Sub>-C<com:Sub>6< / com:Sub>. The cycloalkyl component is as defined above. Exemplary cycloalkyl-alkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and cyclohexylmethyl.

[0042] "Alkoxy" refers to an alkyl group having an oxygen atom that connects the alkyl group to the point of attachment: alkyl-O-. Alkoxy groups can have any suitable number of carbon atoms, such as C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, hexoxy, etc.

[0043] "Hydroxyalkyl" refers to an alkyl group, as defined above, where at least one of the hydrogen atoms is replaced with a hydroxy group. As for the alkyl group, a hydroxyalkyl group can have any suitable number of carbon atoms, such as C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>. Exemplary hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl (where the hydroxy is in the 1- or 2-position), hydroxypropyl (where the hydroxy is in the 1-, 2- or 3-position), hydroxybutyl (where the hydroxy is in the 1-, 2-, 3- or 4-position), hydroxypentyl (where the hydroxy is in the 1-, 2-, 3-, 4- or 5-position), hydroxyhexyl (where the hydroxy is in the 1-, 2-, 3-, 4-, 5- or 6-position), 1,2-dihydroxyethyl, and the like. 100441 "Alkoxyalkyl" refers to a radical having an alkyl component and an alkoxy component, where the alkyl component links the alkoxy component to the point of attachment. The alkyl component is as defined above, except that the alkyl component is at least divalent, an alkylene, to link to the alkoxy component and to the point of attachment. The alkyl component can include any number of carbons, such as <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>4< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>5< / com:Sub>, C<com:Sub>3< / com:Sub>-C<com:Sub>6< / com:Sub>, C<com:Sub>4< / com:Sub>-C<com:Sub>5< / com:Sub>, C<com:Sub>4< / com:Sub>-C<com:Sub>6< / com:Sub> and C<com:Sub>5< / com:Sub>-C<com:Sub>6< / com:Sub>. The alkoxy component is as defined above. Examples of the alkoxy-alkyl group include, but are not limited to, 2-ethoxy-ethyl and methoxymethyl.

[0045] "Halogen" or "halo" refers to fluoro, chloro, bromo, or iodo.

[0046] "Haloalkyl" refers to alkyl, as defined above, where some or all of the hydrogen atoms are replaced with halogen atoms. As for alkyl group, haloalkyl groups can have any suitable number of carbon atoms, such as <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>. For example, haloalkyl includes trifluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, etc. In some instances, the term "perfluoro" can be used to define a compound or radical where all the hydrogens are replaced with fluorine. For example, perfluoromethyl refers to 1,1,1-trifluoromethyl.

[0047] "Amino" as used herein, and unless otherwise specified, refers to -NH<com:Sub>2< / com:Sub>.

[0048] "Alkylamino" as used herein, and unless otherwise specified, refers to an -NHR radical where R is alkyl as defined herein, or an N-oxide derivative thereof. In some embodiments, alkylamino is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-alkyl-amino. In some embodiments, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-alkyl-amino is methylamino, ethylamino, <com:Math><semantics>n<annotation encoding="application / x-tex">n< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>iso<annotation encoding="application / x-tex">iso< / annotation>< / semantics>< / com:Math>-propylamino, <com:Math><semantics>n<annotation encoding="application / x-tex">n< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>iso<annotation encoding="application / x-tex">iso< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>tert<annotation encoding="application / x-tex">tert< / annotation>< / semantics>< / com:Math>-butylamino, or methylamino-N-oxide, and the like.

[0049] "Dialkylamino" as used herein, and unless otherwise specified, refers to an -NR'R radical where R and R' are independently alkyl as defined herein, or an N-oxide derivative thereof. In some embodiments, dialkylamino is di-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-alkyl-amino. In some embodiments, di-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-alkyl-amino is dimethylamino, methyl-ethylamino, diethylamino, or dimethylamino-N-oxide, and the like.

[0050] "Aminoalkyl" as used herein, unless otherwise specified, refers to an alkyl group substituted with one or two NH<com:Sub>2< / com:Sub>. In some embodiments, aminoalkyl is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-alkyl.

[0051] "Alkylaminoalkyl" as used herein, unless otherwise specified, refers to an alkyl group substituted with one or two -NH(alkyl) groups. In some embodiments, alkylaminoalkyl is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>- alkyl-amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-alkyl.

[0052] "Dialkylaminoalkyl" as used herein, unless otherwise specified, refers to an alkyl group substituted with one or two -N(alkyl)<com:Sub>2< / com:Sub> groups. In some embodiments, dialkylaminoalkyl is di-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-alkyl-amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-alkyl.

[0053] "Hydroxyamino" as used herein, unless otherwise specified, refers to -NHOH.

[0054] "N-alkylhydroxyamino" as used herein, unless otherwise specified, refers to the amine hydrogen of -NHOH is substituted with alkyl as defined herein. In some embodiments, N-alkyl hydroxyamino is N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl-hydroxyamino. In some embodiments, N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl- hydroxyamino is <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>-methylhydroxyamino, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>-ethylhydroxyamino, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(n<annotation encoding="application / x-tex">(n< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>iso<annotation encoding="application / x-tex">iso< / annotation>< / semantics>< / com:Math>-propyl)- hydroxyamino, or <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(n<annotation encoding="application / x-tex">(n< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>iso<annotation encoding="application / x-tex">iso< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>tert<annotation encoding="application / x-tex">tert< / annotation>< / semantics>< / com:Math>-butyl)hydroxyamino, and the like.

[0055] "Heterocycloalkyl" refers to a saturated ring system having from 3 to 12 ring members and from 1 to 4 heteroatoms of N, O and S. The heteroatoms can also be oxidized, such as, but not limited to, -S(O)- and -S(O)<com:Sub>2< / com:Sub>-. Heterocycloalkyl groups can include any number of ring atoms, such as, 3 to 6, 4 to 6, 5 to 6, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 3 to 9, 3 to 10, 3 to 11, or 3 to 12 ring members. Any suitable number of heteroatoms can be included in the heterocycloalkyl groups, such as 1, 2, 3, or 4, or 1 to 2, 1 to 3, 1 to 4, 2 to 3, 2 to 4, or 3 to 4. The heterocycloalkyl group can include groups such as aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, azocanyl, quinuclidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl (1,2-, 1,3- and 1,4-isomers), oxiranyl, oxetanyl, tetrahydrofuranyl, oxanyl (tetrahydropyranyl), oxepanyl, thiiranyl, thietanyl, thiolanyl (tetrahydrothiophenyl), thianyl (tetrahydrothiopyranyl), oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, morpholinyl, thiomorpholinyl, dioxanyl, or dithianyl. The heterocycloalkyl groups can also be fused to aromatic or non-aromatic ring systems to form members including, but not limited to, indoline. Heterocycloalkyl groups can be unsubstituted or substituted. For example, heterocycloalkyl groups can be substituted with <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl or oxo (=0), among many others. 100561 The heterocycloalkyl groups can be linked via any position on the ring. For example, aziridinyl can be 1- or 2- aziridinyl, azetidinyl can be 1- or 2- azetidinyl, pyrrolidinyl can be 1-, 2- or 3-pyrrolidinyl, piperidinyl can be 1-, 2-, 3- or 4-piperidinyl, pyrazolidinyl can be 1-, 2-, 3-, or 4-pyrazolidinyl, imidazolidinyl can be 1-, 2-, 3- or 4-imidazolidinyl, piperazinyl can be 1-, 2-, 3- or 4-piperazinyl, tetrahydrofuranyl can be 1- or 2-tetrahydrofuranyl, oxazolidinyl can be 2-, 3- , 4- or 5-oxazolidinyl, isoxazolidinyl can be 2-, 3-, 4- or 5-isoxazolidinyl, thiazolidinyl can be 2-, 3-, 4- or 5-thiazolidinyl, isothiazolidinyl can be 2-, 3-, 4- or 5- isothiazolidinyl, and morpholinyl can be 2-, 3- or 4-morpholinyl.

[0057] "N-linked heterocycloalkyl" or "nitrogen-linked heterocycloalkyl" refers to the heterocycloalkyl group linked via N-position on the ring. For example, N-linked aziridinyl is aziridin-1-yl, N-linked azetidinyl is azetidin-1-yl, N-linked pyrrolidinyl is pyrrolidin-1-yl, N- linked piperidinyl is piperidin-1-yl, N-linked pyrazolidinyl is pyrazolidin-1-yl or pyrazolidin-2- yl, N-linked imidazolidinyl can be imidazolidin-1-yl or imidazolidin-3-yl, N-linked piperazinyl is piperazin-1-yl or piperazin-4-yl, N-linked oxazolidinyl is oxazolidin-3-yl, N-linked isoxazolidiny is isoxazolidin-2-yl, N-linked thiazolidinyl is thiazolidin-3-yl, N-linked isothiazolidinyl is isothiazolidin-2-yl, and N-linked morpholinyl is 4-morpholinyl.

[0058] When heterocycloalkyl includes 3 to 8 ring members and 1 to 3 heteroatoms, representative members include, but are not limited to, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, oxanyl, tetrahydrothiophenyl, thianyl, pyrazolidinyl, imidazolidinyl, piperazinyl, oxazolidinyl, isoxzoalidinyl, thiazolidinyl, isothiazolidinyl, morpholinyl, thiomorpholinyl, dioxanyl and dithianyl. Heterocycloalkyl can also form a ring having 5 to 6 ring members and 1 to 2 heteroatoms, with representative members including, but not limited to, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, and morpholinyl.

[0059] "Protecting group" refers to a compound that renders a functional group unreactive to a particular set of reaction conditions, but that is then removable in a later synthetic step so as to restore the functional group to its original state. Such protecting groups are well known to one of ordinary skill in the art and include compounds that are disclosed in "Protective Groups in Organic Synthesis", 4th edition, T. W. Greene and P. G. M. Wuts, John Wiley & Sons, New York, 2006.

[0060] "Salt" refers to acid or base salts of the compounds of the present invention. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985.

[0061] Pharmaceutically acceptable salts of the acidic compounds of the present invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris-(hydroxymethyl)-methyl-ammonium salts.

[0062] Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids, e.g., hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.

[0063] The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

[0064] "Isomer" refers to compounds with the same chemical formula but which are structurally distinguishable. Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.

[0065] "Tautomer" refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one form to another.

[0066] "Solvate" refers to a compound provided herein or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.

[0067] "Hydrate" refers to a compound that is complexed to at least one water molecule. The compounds of the present invention can be complexed with from 1 to 10 water molecules.

[8800] "Substantially free of" or "substantially in the absence of" stereoisomers with respect to a composition refers to a composition that includes at least 85 or 90% by weight, In some embodiments 95%, 98 %, 99% or 100% by weight, of a designated stereoisomer of a compound in the composition. In some embodiments, in the methods and compounds provided herein, the compounds are substantially free of stereoisomers.

[0069] "Isolated" with respect to a composition refers to a composition that includes at least 85%, 90%, 95%, 98%, 99% to 100% by weight, of a specified compound, the remainder comprising other chemical species or stereoisomers.

[0070] "Composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and deleterious to the recipient thereof.

[0071] "Pharmaceutically acceptable excipient" refers to a substance that aids the administration of an active agent to and absorption by a subject. Pharmaceutical excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.

[0072] "IC<com:Sub>50< / com:Sub>" refers to an amount, concentration or dosage of a particular test compound that achieves a 50% inhibition of a maximal response in an assay that measures such response.

[0073] "Inhibition", "inhibits" and "inhibitor" refer to a compound that prohibits or a method of prohibiting, a specific action or function.

[0074] "Administering" refers to oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to the subject.

[0075] "Treat", "treating" and "treatment" refer to any indicia of success in the treatment or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and / or a psychiatric evaluation.

[0076] "Treating" or "treatment" of a birthmark, in some embodiments, refers to ameliorating the appearance or severity of the birthmark that exists in a subject. In some embodiments, "treating" or "treatment" includes ameliorating at least one physical parameter. In some embodiments, "treating" or "treatment" includes modulating the appearance of a birthmark physically (e.g., stabilization or reduction of a discernible symptom or characteristic of the birthmark, such as the size, volume, color, thickness, and / or texture of the birthmark). In some embodiments, "treating" or "treatment" includes the reduction or elimination of one or more of the following: size, color, thickness, and / or texture of the birthmark.

[0077] "Prophylactically treating" and "preventing" malignant progression of a birthmark, in some embodiments, refer to reducing the risk in a subject of the malignant progression of a birthmark. In some embodiments, "prophylactically treating" or "preventing" includes delaying the onset of a malignancy which results from a birthmark. In some embodiments, "prophylactically treating" or "preventing" includes retarding the progression of the birthmark to a malignancy or of ameliorating the one or more symptoms associated with the progression of a birthmark to malignancy.

[0078] "Patient" or "subject" refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, the patient is human.

[0079] "Therapeutically effective amount" or "effective amount" refers to an amount of a compound or of a pharmaceutical composition useful for treating or ameliorating an identified disease or condition (e.g., a birthmark as described herein), or for exhibiting a detectable therapeutic or inhibitory effect. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

[0800] "Therapeutically effective amount" or "Effective amount", in some embodiments, refers to an amount of a compound or composition that, when administered to a subject for treating the appearance of a birthmark, is sufficient to alter the appearance of the birthmark. An "effective amount" can vary depending on, inter alia, the compound, the birthmark and its severity, the size of the birthmark to be treated, and the age, weight, etc., of the subject to be treated.

[0081] "Topical" means application of a suitable compound (e.g. active agent) or composition comprising a compound (e.g. active agent) to the skin to treat a birthmark. "Subcutaneous" means application of a suitable compound (e.g. active agent) or composition comprising a compound (e.g. active agent) to the layers below the epidermis and dermis. "Intradermal" means application of a suitable compound (e.g. active agent) or composition comprising a compound (e.g. active agent) in the dermal or hypodermal layers. Intralesional" means injection of a suitable compound (e.g. active agent) or composition comprising a compound (e.g. active agent) at the site of the lesion (e.g. birthmark).

[0082] In some embodiments, "topical" means application of a suitable compound (e.g. active agent) or composition comprising a compound (e.g. active agent) to the skin with adequate penetration of the epidermis or dermis to treat the birthmark of the epidermis and / or dermis. In some embodiments of topical application, the compound or composition penetrates the epidermis or dermis without significant systemic exposure nor intent to treat or prevent a disease of another organ system. In some embodiments, "subcutaneous" means injection of a suitable compound (e.g. active agent) or composition comprising a compound (e.g. active agent) into the layers below the epidermis and dermis. In some embodiments, "intradermal" means injection of a compound (e.g. active agent) or composition comprising a compound (e.g. active agent) into the dermal layers. In some embodiments, "intralesional" means injection of a compound (e.g. active agent) or composition comprising a compound (e.g. active agent) directly into a lesion, such as a birthmark, with the objective of treating a birthmark or a lesion.

[0083] The disclosure provides "soft" MEK inhibitors, compositions comprising "soft" MEK inhibitors, and methods of treating and / or ameliorating a birthmark (e.g., a MEK-inhibitor responsive or MEK-mediated birthmark). For example, the methods described herein provide administration, e.g., local or non-systemic, e.g., topical, subcutaneous, transdermal, intradermal, or intralesional administration, of MEK inhibitors, e.g., "soft" MEK inhibitors, e.g., "soft" MEK inhibitors described herein, whereby one or more side effects exhibited with systemic exposure, e.g., known one or more side effects exhibited with MEK inhibitors designed for systemic delivery, are significantly reduced.

[0084] In some embodiments, "soft MEK inhibitor" is a compound which inhibits MEK1 and / or 2 and is characterized by a predictable and controllable metabolism / degradation to non- toxic and biologically less active or inactive (i.e. does not inhibit, or inhibits to a lesser degree, MEK1 and / or 2) products after they have achieved their therapeutic role in the skin.

[0085] "Hard MEK inhibitor" refers to a MEK inhibitor known in the art. In some embodiments, a hard MEK inhibitor is designed for oral bioavailability. This is necessary to deliver therapeutically effective levels of MEK inhibitor to peripheral lesions with systemic delivery. Hard MEK inhibitor include, for example, PD0325901; PD184161; SMK-17; AS703026 (Pimasertib, MSC1936369); RO-4987655; Selumetinib (AZD6244, ARRY142886); Binimetinib (MEK162, ARRY-162, ARRY-438162); Refametinib; Cobimetinib (GDC-0973, XL518); GDC-0623; AZD8330 (ARRY-424704); Cl-1040 (PD184352); PD198306; Trametinib; RO-4987655; GDC-0623; TAK-733; WX-554; CH5126766 (also as RO5126766); G-573; Arry 300; SHR 7390; MSC2015103B (also known as AS-703988); CS 3006; and LY 2228820 (also know as Ralimetinib).

[0086] While not wishing to be bound by theory, it is believed that soft MEK inhibitors, e.g., such as the "soft" MEK inhibitors described herein, are more metabolically labile than known "hard" MEK inhibitors. Due to their inherent metabolic instability, e.g., for degradation upon reaching the systemic circulation, "soft" MEK inhibitors, e.g., such as the "soft" MEK inhibitors described herein, are dermally active but have low systemic exposure upon local or non-systemic administration, e.g., topical, subcutaneous, intradermal, or intralesional administration, because they rapidly degrade upon exposure to plasma or blood or hepatic metabolic enzymes. Unlike "soft" MEK inhibitors, known MEK inhibitors have been historically designed for oral bioavailability, which requires good stability in plasma or blood and good stability to hepatic metabolism necessary to permit systemic delivery at therapeutically effective or effective levels, and are more prone to one or more unwanted side effects and increased toxicity. As a result, "soft" MEK inhibitors, e.g., such as the soft MEK inhibitors described herein, are less systemically toxic.

[0087] "A," "an," or "a(n)", when used in reference to a group of substituents or "substituent group" herein, mean at least one. For example, where a compound is substituted with "an" alkyl or aryl, the compound is optionally substituted with at least one alkyl and / or at least one aryl, wherein each alkyl and / or aryl is optionally different. In another example, where a compound is substituted with "a" substitutent group, the compound is substituted with at least one substituent group, wherein each substitutent group is optionally different. III. METHODS

[0088] In one aspect, provided herein is a method of treating a birthmark. The method includes administering to a subject in need thereof a therapeutically effective amount or an effective amount of a compound selected from the group consisting of formula (I), (II), (IV), and (V): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (I), (II), [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (III), (IV), and [Image disponible dans le document PDF, Image available in the PDF document] ), or a N-oxide, stereoisomer, mixture of stereoisomers, and / or a pharmaceutically acceptable salt thereof, wherein: <com:Math><semantics>X1<annotation encoding="application / x-tex">X^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−CR13b<annotation encoding="application / x-tex">-CR^{13b}< / annotation>< / semantics>< / com:Math> or N; <com:Math><semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; <com:Math><semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics>< / com:Math> is S or O; subscript n is an integer from 0 to 2; bond "a" is a single or double bond; R1 is -OR4, -NR5R5a, -N(OR5b)R5a, or a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>; R<com:Sup>2< / com:Sup> is halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl; <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is halo or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; R<com:Sup>4< / com:Sup>, R<com:Sup>5< / com:Sup>, and R<com:Sup>5b< / com:Sup> are each independently hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R5a<annotation encoding="application / x-tex">R^{5a}< / annotation>< / semantics>< / com:Math> is hydrogen or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, oxo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl hydroxyamino; R<com:Sup>13< / com:Sup>, R<com:Sup>13a< / com:Sup>, and R<com:Sup>13b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl; R<com:Sup>23< / com:Sup>, R<com:Sup>23a< / com:Sup>, and R<com:Sup>23b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, or C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkoxy; R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, or C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkoxy; <com:Math><semantics>R43<annotation encoding="application / x-tex">R^{43}< / annotation>< / semantics>< / com:Math> is cyano, <com:Math><semantics>−C(O)NR48R48a<annotation encoding="application / x-tex">-C(O)NR^{48}R^{48a}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(O)R46<annotation encoding="application / x-tex">-C(O)R^{46}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R43a<annotation encoding="application / x-tex">R^{43a}< / annotation>< / semantics>< / com:Math> is hydrogen, halo, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; or R<com:Sup>43< / com:Sup> and R<com:Sup>43a< / com:Sup> together form -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)- or -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)-, each of which is unsubstituted or substituted with one or two R<com:Sup>49< / com:Sup>; R<com:Sup>46< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl or heterocycloalkyl; R<com:Sup>48< / com:Sup> and R<com:Sup>48a< / com:Sup> are independently hydrogen or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each R<com:Sup>49< / com:Sup> is independently C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, or C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; R<com:Sup>51< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or -OR<com:Sup>54< / com:Sup>, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup>; each <com:Math><semantics>R53<annotation encoding="application / x-tex">R^{53}< / annotation>< / semantics>< / com:Math> is independently halo or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; R<com:Sup>53a< / com:Sup> and R<com:Sup>53b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl; and R<com:Sup>54< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>.

[0089] In some embodiments, the method includes administering the subject in need thereof a therapeutically effective amount or an effective amount of a compound disclosed herein, e.g., a compound having any one of formula (I), (II), (III), (IV), and (V), and compounds in Tables 1-5, including a single enantiomer, a mixture of an enantiomeric pair, an individual diastereomer, a mixture of diastereomers, an individual stereoisomer, a mixture of stereoisomers, or a tautomeric form thereof; or a pharmaceutically acceptable salt, solvate, prodrug, phosphate, or active metabolite thereof.

[0090] In some embodiments, the method includes administering the subject in need thereof a therapeutically effective amount or an effective amount of a compound having formula (I) and compounds in Table 1, including a single enantiomer, a mixture of an enantiomeric pair, an individual diastereomer, a mixture of diastereomers, an individual stereoisomer, a mixture of stereoisomers, or a tautomeric form thereof; or a pharmaceutically acceptable salt or solvate thereof.

[0091] In some embodiments, the method includes administering the subject in need thereof a therapeutically effective amount or an effective amount of a compound having formula (II) and compounds in Table 2, including a single enantiomer, a mixture of an enantiomeric pair, an individual diastereomer, a mixture of diastereomers, an individual stereoisomer, a mixture of stereoisomers, or a tautomeric form thereof; or a pharmaceutically acceptable salt or solvate thereof.

[0092] In some embodiments, the method includes administering the subject in need thereof a therapeutically effective amount or an effective amount of a compound having formula (III) and compounds in Table 3, including a single enantiomer, a mixture of an enantiomeric pair, an individual diastereomer, a mixture of diastereomers, an individual stereoisomer, a mixture of stereoisomers, or a tautomeric form thereof; or a pharmaceutically acceptable salt or solvate thereof.

[0093] In some embodiments, the method includes administering the subject in need thereof a therapeutically effective amount or an effective amount of a compound having formula (IV) and compounds in Table 4, including a single enantiomer, a mixture of an enantiomeric pair, an individual diastereomer, a mixture of diastereomers, an individual stereoisomer, a mixture of stereoisomers, or a tautomeric form thereof; or a pharmaceutically acceptable salt or solvate thereof.

[0094] In some embodiments, the method includes administering the subject in need thereof a therapeutically effective amount or an effective amount of a compound having formula (V) and compounds in Table 5, including a single enantiomer, a mixture of an enantiomeric pair, an individual diastereomer, a mixture of diastereomers, an individual stereoisomer, a mixture of stereoisomers, or a tautomeric form thereof; or a pharmaceutically acceptable salt or solvate thereof.

[0095] In some embodiments, the birthmark is a port-wine stain (capillary malformation). In some embodiments, provided herein is a method of treating a port-wine stain (capillary malformation) birthmark to reduce the cosmetic disfigurement or progression of the birthmark. In some embodiments, provided herein is a method of prophylactically treating a port-wine stain (capillary malformation) birthmark to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0096] In some embodiments, the birthmark is epidermal nevi. In some embodiments, provided herein is a method of treating epidermal nevi to reduce the cosmetic disfigurement or progression of the birthmark. In some embodiments, provided herein is a method of prophylactically treating epidermal nevi to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0097] In some embodiments, the birthmark is nevus sebaceous. In some embodiments, provided herein is a method of treating a nevus sebaceous birthmark to reduce the cosmetic disfigurement or progression of the birthmark. In some embodiments, provided herein is a method of prophylactically treating a nevus sebaceous birthmark to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0098] In some embodiments the birthmark is nevus cellular nevi. In some embodiments, provided herein is a method of treating nevus cellular nevi to reduce the cosmetic disfigurement or progress of the birthmark. In some embodiments, provided herein is a method of prophylactically treating nevus cellular nevi to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0099] In some embodiments, the birthmark is dysplastic nevi. In some embodiments, provided herein is a method of treating dysplastic nevi to reduce the cosmetic disfigurement or progression of the birthmark. In some embodiments, provided herein is a method of prophylactically treating dysplastic nevi to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0100] In some embodiments, the birthmark is a nevus spilus. In some embodiments, provided herein is a method of treating a nevus spilus birthmark to reduce the cosmetic disfigurement or progression of the birthmark. In some embodiments, provided herein is a method of prophylactically treating a nevus spilus birthmark to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0101] In some embodiments, the birthmark is an arterio-venous malformation in the skin. In some embodiments, provided herein is a method of treating an arterio-venous malformation to reduce the cosmetic disfigurement or progression of the birthmark. In some embodiments, provided herein is a method of prophylactically treating an arterio-venous malformation to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0102] In some embodiments, the birthmark is a lymphatic malformation. In some embodiments, provided herein is a method of treating a lymphatic malformation to reduce the risk of the cosmetic disfigurement or progression of the birthmark. In some embodiments, provided herein is a method of prophylactically treating a lymphatic malformation to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0103] In some embodiments, the birthmark is a congenital melanocytic nevus. In some embodiments, provided herein is a method of treating a congenital melanocytic nevus to reduce the risk of cosmetic disfigurement or progression of the birthmark. In some embodiments, provided herein is a method of prophylactically treating a congenital melanocytic nevus to prevent the progression of the birthmark, delaying the onset of the birthmark, or delaying the progression of the birthmark.

[0104] In some embodiments, the compounds described herein are used for the reduction of a birthmark in a subject in need thereof.

[0105] In some embodiments, the compounds described herein are used for the amelioration of a birthmark in a subject in need thereof

[0106] In some embodiments, the compounds described herein are used for prevention of a birthmark (e.g., a MEK-inhibitor responsive or MEK-mediated birthmark) and / or prevention of worsening of a birthmark (e.g., where the birthmark may progress to a proliferative disease) in a subject in need thereof.

[0107] In some embodiments, the subject in need thereof is a human.

[0108] The birthmark is not cafe au lait spots.

[0109] In some embodiments, administering includes contacting the soft MEK inhibitor with the skin of the subject, e.g., an affected region of the skin, e.g., a region of the skin having a birthmark.

[0110] In some embodiments, the appearance of a birthmark is reduced, e.g., the size, volume, or the total surface area is reduced, by at least about 15% relative to the reference standard (e.g., the size of the birthmark prior to start of treatment), thereby treating the subject. In some embodiments, the size, volume, or the total surface area on skin is reduced, by at least about 15%, by at least about 20%, by at least about 25%, by at least about 30%, by at least about 35%, by at least about 40%, by at least about 45%, by at least about 50%, by at least about 55%, by at least about 60% relative to the reference standard. In some embodiments, the reference standard is the size of the birthmark prior to start of treatment. Assay Methods

[0111] Compounds can be assayed for efficacy in treating a birthmark (e.g., a MEK-inhibitor responsive or MEK-mediated birthmark) where the subject is in need thereof according to any assay known to those of skill in the art. Exemplary assay methods are provided elsewhere herein. IV. COMPOUNDS

[0112] The present invention provides a compound for use in the method for treating a birthmark as defined and decribed herein, wherein the compound is selected from the group consisting of formula (I), (II), (III), (IV), and (V): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (I), [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (III), (IV), and [Image disponible dans le document PDF, Image available in the PDF document] - or a N-oxide, stereoisomer, mixture of stereoisomers, and / or a pharmaceutically acceptable salt thereof, wherein: [Image disponible dans le document PDF, Image available in the PDF document] subscript n is an integer from 0 to 2; bond "a" is a single or double bond; R<com:Sup>1< / com:Sup> is -OR<com:Sup>4< / com:Sup>, -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup>, -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup>, or a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>; R<com:Sup>2< / com:Sup> is halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl; <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is halo or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; R<com:Sup>4< / com:Sup>, R<com:Sup>5< / com:Sup>, and R<com:Sup>5b< / com:Sup> are each independently hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R5a<annotation encoding="application / x-tex">R^{5a}< / annotation>< / semantics>< / com:Math> is hydrogen or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, oxo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy, amino, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkylamino, di-<com:Math><semantics>(C1<annotation encoding="application / x-tex">(C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl)amino, hydroxyamino, or <com:Math><semantics>N−C1−C6<annotation encoding="application / x-tex">N-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl hydroxyamino; <com:Math><semantics>R8<annotation encoding="application / x-tex">R^8< / annotation>< / semantics>< / com:Math> is hydroxy, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math> alkyl, or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math> alkoxy; R<com:Sup>13< / com:Sup>, R<com:Sup>13a< / com:Sup>, and R<com:Sup>13b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl; R<com:Sup>23< / com:Sup>, R<com:Sup>23a< / com:Sup>, and R<com:Sup>23b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy, or <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math> cycloalkoxy; R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, or C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkoxy; <com:Math><semantics>R43<annotation encoding="application / x-tex">R^{43}< / annotation>< / semantics>< / com:Math> is cyano, -C(O)NR<com:Sup>48< / com:Sup>R<com:Sup>48a< / com:Sup>, or -C(O)R<com:Sup>46< / com:Sup>; R<com:Sup>43a< / com:Sup> is hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; or R<com:Sup>43< / com:Sup> and R<com:Sup>43a< / com:Sup> together form -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)- or -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)-, each of which is unsubstituted or substituted with one or two R<com:Sup>49< / com:Sup>; R<com:Sup>46< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl or heterocycloalkyl; R<com:Sup>48< / com:Sup> and R<com:Sup>48a< / com:Sup> are independently hydrogen or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each R<com:Sup>49< / com:Sup> is independently C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, or C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; R<com:Sup>51< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or -OR<com:Sup>54< / com:Sup>, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>; each <com:Math><semantics>R53<annotation encoding="application / x-tex">R^{53}< / annotation>< / semantics>< / com:Math> is independently halo or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; R<com:Sup>53a< / com:Sup> and R<com:Sup>53b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl; and R<com:Sup>54< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino- <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, di-<com:Math><semantics>(C1<annotation encoding="application / x-tex">(C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl)amino-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, heterocycloalkyl, heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein each of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to <com:Math><semantics>sixR6<annotation encoding="application / x-tex">six R^6< / annotation>< / semantics>< / com:Math>.

[0113] In some embodiments, the cycloalkyl group provided in formula (I), (II), (III), (IV) and (V) is a saturated monocyclic <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math> cycloalkyl. In some embodiments, the <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math> cycloalkyl group, as alone or as part of C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl is cyclopropyl or cyclobutyl. In some embodiments, the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group, as alone or as part of C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, is unsubstituted. In some embodiments, the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group, as alone or as part of C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, is substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein.

[0114] With reference to R<com:Sup>6< / com:Sup> as one or more substituents of the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group, in some embodiments, each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, oxo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>- hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>- hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, or di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino. In some embodiments, each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, or amino. In some embodiments, each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, each R<com:Sup>6< / com:Sup> is independently hydroxy or amino.

[0115] In some embodiments, the heterocycloalkyl group provided in formula (I), (II), (IV) and (V) is a 3 to 8 membered heterocycloalkyl having 1 to 3 ring member heteroatoms selected from N, O, and S. In some embodiments, heterocycloalkyl is a 3 to 6 membered heterocycloalkyl having 1 to 2 heteroatoms of N or O. In some embodiments, the heterocycloalkyl group, as alone or as part of heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, is unsubstituted. In some embodiments, the heterocycloalkyl group, as alone or as part of heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, is substituted one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, the N-linked heterocycloalkyl group is substituted one or two R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein.

[0116] With reference to R<com:Sup>6< / com:Sup> as one or more substituents of the heterocycloalkyl group or the N-linked heterocycloalkyl, in some embodiments, each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, oxo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C1-C6 alkyl)amino, amino-C1-C6 alkyl, C1-C6 alkylamino-C1-C6 alkyl, or di-(C1-C6 alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, oxo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub>-hydroxyalkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, or di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino. In some embodiments, each R<com:Sup>6< / com:Sup> is independently halo, hydroxy, oxo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, or amino. In some embodiments, each R<com:Sup>6< / com:Sup> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, each <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is independently hydroxy, oxo, or amino. In some embodiments, each R<com:Sup>6< / com:Sup> is independently hydroxy or amino.

[0117] In some embodiments, the compounds useful in the present methods are compounds of formula (I).

[0118] With reference to formula (I), in some embodiments, X<com:Sup>1< / com:Sup> is -CR<com:Sup>13b< / com:Sup>, and the compound is represented by formula (la): [Image disponible dans le document PDF, Image available in the PDF document] (Ia), wherein R<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>13< / com:Sup>, R<com:Sup>13a< / com:Sup>, and R<com:Sup>13b< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0119] In some embodiments of formula (Ia), R<com:Sup>13< / com:Sup>, R<com:Sup>13a< / com:Sup>, and R<com:Sup>13b< / com:Sup> are each independently hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl.

[0120] In some embodiments of formula (Ia), R<com:Sup>13< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>13< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>13< / com:Sup> is halo. In some embodiments, R<com:Sup>13< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>13< / com:Sup> is fluoro. In some embodiments, R<com:Sup>13< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>13< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>13< / com:Sup> is methyl.

[0121] In some embodiments of formula (Ia), R<com:Sup>13a< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>13a< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>13a< / com:Sup> is halo. In some embodiments, R<com:Sup>13a< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>13a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>13a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>13a< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>13a< / com:Sup> is methyl.

[0122] In some embodiments of formula (Ia), R<com:Sup>13b< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>13b< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>13b< / com:Sup> is halo. In some embodiments, R<com:Sup>13b< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>13b< / com:Sup> is fluoro. In some embodiments, R<com:Sup>13b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>13b< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>13b< / com:Sup> is methyl.

[0123] In some embodiments of formula (la), R<com:Sup>13< / com:Sup>, R<com:Sup>13a< / com:Sup>, and R<com:Sup>13b< / com:Sup> are each hydrogen. In some embodiments of formula (Ia), R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> are each hydrogen and R<com:Sup>13b< / com:Sup> is halo. In some embodiments of formula (Ia), R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> are each hydrogen and R<com:Sup>13b< / com:Sup> is fluoro.

[0124] Returning to formula (I), in some embodiments, X<com:Sup>1< / com:Sup> is N, and the compound is represented by formula (lb): [Image disponible dans le document PDF, Image available in the PDF document] (Ib), wherein R<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>13< / com:Sup>, and R<com:Sup>13a< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0125] In some embodiments of formula (Ib), R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> are each independently hydrogen, halo, or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl.

[0126] In some embodiments of formula (Ib), R<com:Sup>13< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>13< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>13< / com:Sup> is halo. In some embodiments, R<com:Sup>13< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>13< / com:Sup> is fluoro. In some embodiments, R<com:Sup>13< / com:Sup> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R13<annotation encoding="application / x-tex">R^{13}< / annotation>< / semantics>< / com:Math> is methyl.

[0127] In some embodiments of formula (Ib), R<com:Sup>13a< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>13a< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>13a< / com:Sup> is halo. In some embodiments, R<com:Sup>13a< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>13a< / com:Sup> is fluoro. In some embodiments, <com:Math><semantics>R13a<annotation encoding="application / x-tex">R^{13a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R13a<annotation encoding="application / x-tex">R^{13a}< / annotation>< / semantics>< / com:Math> is methyl.

[0128] In some embodiments of formula (Ib), R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> are each independently hydrogen or halo. In some embodiments, R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> are each hydrogen. In some embodiments, one of R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> is hydrogen and the other is halo. In some embodiments, one of R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> is hydrogen and the other is fluoro.

[0129] With reference to any one of formulae (I), (Ia), and (Ib), in some embodiments, R<com:Sup>1< / com:Sup> is <com:Math><semantics>−OR4<annotation encoding="application / x-tex">-OR^4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5R5a<annotation encoding="application / x-tex">-NR^5R^{5a}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(OR5b)R5a<annotation encoding="application / x-tex">-N(OR^{5b})R^{5a}< / annotation>< / semantics>< / com:Math>.

[0130] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>1< / com:Sup> is -OR<com:Sup>4< / com:Sup>. In some embodiments, R<com:Sup>4< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl- <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, or cyclobutyl-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R4 is C1-C6 hydroxyalkyl. In some embodiments, R4 is C1-C6 alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl- 1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or <com:Math><semantics>N−C1−C6<annotation encoding="application / x-tex">N-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl hydroxyamino. In some embodiments, <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>R7−C(O)−C1−C6<annotation encoding="application / x-tex">R^7-C(O)-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydroxyamino.

[0131] In some embodiments of any one of formulae (1), (la), and (lb), R<com:Sup>1< / com:Sup> is selected from the group consisting of -OH, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]

[0132] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>1< / com:Sup> is -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup>. In some embodiments, R<com:Sup>5< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl- <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, or cyclobutyl-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl- 1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy, amino, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkylamino, di-<com:Math><semantics>(C1<annotation encoding="application / x-tex">(C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl)amino, hydroxyamino, or <com:Math><semantics>N−C1−C6<annotation encoding="application / x-tex">N-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl hydroxyamino. In some embodiments, <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>R7−C(O)−C1−C6<annotation encoding="application / x-tex">R^7-C(O)-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydroxyamino.

[0133] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>1< / com:Sup> is -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup> and R<com:Sup>5< / com:Sup> is selected from the group consisting of hydrogen, [Image disponible dans le document PDF, Image available in the PDF document]

[0134] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>1< / com:Sup> is -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup>. In some embodiments, R<com:Sup>5b< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5b<annotation encoding="application / x-tex">R^{5b}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> hydroxyalkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R5b is heterocycloalkyl unsubstituted or substituted with one to six R6 and each R6 is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5b<annotation encoding="application / x-tex">R^{5b}< / annotation>< / semantics>< / com:Math> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl- C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl-1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl hydroxyamino. In some embodiments, R5b is R7-C(O)-C1-C6 alkyl; and R7 is hydroxy, C1-C6 alkoxy, amino, or hydroxyamino.

[0135] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>1< / com:Sup> is -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup> and -OR<com:Sup>5b< / com:Sup> is selected from the group consisting of -OH, [Image disponible dans le document PDF, Image available in the PDF document]

[0136] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>5a< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl. In some embodiments, R<com:Sup>5a< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl. In some embodiments, R<com:Sup>5a< / com:Sup> is methyl.

[0137] With reference to any one of formulae (I), (Ia), and (Ib), in some embodiments, R<com:Sup>1< / com:Sup> is a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, the N-linked heterocycloalkyl is N-linked azetidinyl, N-linked pyrrolidinyl, N-linked isoxazolidinyl, N-linked piperidinyl, or N-linked morpholinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked azetidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked pyrrolidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked isoxazolidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked piperidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked morpholinyl. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked azetidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked pyrrolidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked piperidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked isoxazolidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked morpholinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein.

[0138] With reference to R<com:Sup>6< / com:Sup> as one or two substituents of the N-linked heterocycloalkyl in any one of formulae (I), (Ia), and (Ib), in some embodiments, each R<com:Sup>6< / com:Sup> is independently hydroxyl, oxo, or amino. In some embodiments, each R<com:Sup>6< / com:Sup> is hydroxy. In some embodiments, each R<com:Sup>6< / com:Sup> is oxo. In some embodiments, each R<com:Sup>6< / com:Sup> is amino. In some embodiments, one of R<com:Sup>6< / com:Sup> is hydroxy and the other <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is amino.

[0139] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>1< / com:Sup> is a N-linked heterocycloalkyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked azetidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked pyrrolidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked piperidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked isoxazolidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked morpholinyl which is unsubstituted or substituted with hydroxy, oxo, or amino.

[0140] With reference to any one of formulae (1), (Ia), and (Ib), in some embodiments, R<com:Sup>2< / com:Sup> is halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is halo or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is halo,-CH<com:Sub>3< / com:Sub>, -SCH<com:Sub>3< / com:Sub>, C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkynyl.

[0141] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>2< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2< / com:Sup> is iodo. In some embodiments, R<com:Sup>2< / com:Sup> is chloro. In some embodiments, R<com:Sup>2< / com:Sup> is bromo.

[0142] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>2< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is methyl.

[0143] In some embodiments of any one of formulae (1), (Ia), and (Ib), R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub>.

[0144] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>2< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl. In some embodiments, R<com:Sup>2< / com:Sup> is cyclopropyl.

[0145] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>4< / com:Sub> alkenyl. In some embodiments, R<com:Sup>2< / com:Sup> is vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, or butadienyl. In some embodiments, R<com:Sup>2< / com:Sup> is vinyl.

[0146] In some embodiments of any one of formulae (1), (la), and (lb), R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl or propynyl. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl.

[0147] With reference to any one of formulae (1), (Ia), and (Ib), in some embodiments, R<com:Sup>2a< / com:Sup> is halo or C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl. In some embodiments, R<com:Sup>2a< / com:Sup> is halo or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is fluoro or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is iodo or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is chloro or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is bromo or CH<com:Sub>3< / com:Sub>.

[0148] In some embodiments of any one of formulae (I), (Ia), and (Ib), R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2a< / com:Sup> is iodo. In some embodiments, R<com:Sup>2a< / com:Sup> is chloro. In some embodiments, R<com:Sup>2a< / com:Sup> is bromo.

[0149] In some embodiments of any one of formulae (1), (Ia), and (Ib), R<com:Sup>2a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CH3<annotation encoding="application / x-tex">CH_3< / annotation>< / semantics>< / com:Math>.

[0150] With reference to any one of formulae (1), (la), and (lb), in some embodiments, R<com:Sup>2< / com:Sup> and R<com:Sup>2a< / com:Sup> are each halo. In some embodiments, R<com:Sup>2< / com:Sup> is halo and R<com:Sup>2a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is cyclopropyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> and R<com:Sup>2a< / com:Sup> are each independently fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2< / com:Sup> is halo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is bromo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is fluoro.

[0151] In some embodiments, the compound of formula (I) is represented by any one of the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] • . [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] wherein X<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>13< / com:Sup>, and R<com:Sup>13a< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0152] In some embodiments of the above structures having formula (I), X<com:Sup>1< / com:Sup> is -CR<com:Sup>13b< / com:Sup>, and R<com:Sup>13b< / com:Sup> is as defined herein in any aspect or embodiment described herein. In some embodiments of the above structures having formula (I), X<com:Sup>1< / com:Sup> is N.

[0153] In some embodiments of the above structures having formula (I), R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is methyl. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is methyl. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is methyl.

[0154] In some embodiments of the above structures having formula (I), X<com:Sup>1< / com:Sup> is -CR<com:Sup>13b< / com:Sup>; and R<com:Sup>13< / com:Sup>, R<com:Sup>13a< / com:Sup>, and R<com:Sup>13b< / com:Sup> are each hydrogen. In some embodiments of the above structures having formula (1), X<com:Sup>1< / com:Sup> is -CR<com:Sup>13b< / com:Sup>; R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> are each hydrogen and R<com:Sup>13b< / com:Sup> is halo. In some embodiments of the above structures having formula (I), X<com:Sup>1< / com:Sup> is -CR<com:Sup>13b< / com:Sup>; R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> are each hydrogen and R<com:Sup>13b< / com:Sup> is fluoro.

[0155] In some embodiments of the above structures having formula (I), X<com:Sup>1< / com:Sup> is N; R<com:Sup>13< / com:Sup> and R<com:Sup>13a< / com:Sup> are each hydrogen.

[0156] In some embodiments, the compounds useful in the present methods are compounds of formula (II).

[0157] With reference to formula (II), in some embodiments, X<com:Sup>2< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>< / com:Math> is methyl, ethyl, propyl, or isopropyl. In some embodiments, <com:Math><semantics>X2<annotation encoding="application / x-tex">X^2< / annotation>< / semantics>< / com:Math> is methyl and the compound is represented by formula (IIa): [Image disponible dans le document PDF, Image available in the PDF document] (IIa), wherein R<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>23< / com:Sup>, R<com:Sup>23a< / com:Sup>, and R<com:Sup>23b< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0158] In some embodiments of formula (II) or (IIa), R<com:Sup>23< / com:Sup>, R<com:Sup>23a< / com:Sup>, and R<com:Sup>23b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy.

[0159] In some embodiments of formula (II) or (IIa), R<com:Sup>23< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>23< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>23< / com:Sup> is halo. In some embodiments, R<com:Sup>23< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>23< / com:Sup> is fluoro. In some embodiments, R<com:Sup>23< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>23< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>23< / com:Sup> is methyl.

[0160] In some embodiments of formula (II) or (IIa), R<com:Sup>23a< / com:Sup> is hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy. In some embodiments, R<com:Sup>23a< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>23a< / com:Sup> is halo. In some embodiments, <com:Math><semantics>R23a<annotation encoding="application / x-tex">R^{23a}< / annotation>< / semantics>< / com:Math> is fluoro, chloro, bromo, or iodo. In some embodiments, <com:Math><semantics>R23a<annotation encoding="application / x-tex">R^{23a}< / annotation>< / semantics>< / com:Math> is fluoro. In some embodiments, R<com:Sup>23a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>23a< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>23a< / com:Sup> is methyl. In some embodiments, R<com:Sup>23a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy. In some embodiments, R<com:Sup>23a< / com:Sup> is methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, or hexoxy. In some embodiments, R<com:Sup>23a< / com:Sup> is methoxy.

[0161] In some embodiments of formula (II) or (IIa), R<com:Sup>23b< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>23b< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>23b< / com:Sup> is halo. In some embodiments, R<com:Sup>23b< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>23b< / com:Sup> is fluoro. In some embodiments, <com:Math><semantics>R23b<annotation encoding="application / x-tex">R^{23b}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R23b<annotation encoding="application / x-tex">R^{23b}< / annotation>< / semantics>< / com:Math> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>23b< / com:Sup> is methyl.

[0162] In some embodiments of formula (II) or (IIa), R<com:Sup>23< / com:Sup>, R<com:Sup>23a< / com:Sup>, and R<com:Sup>23b< / com:Sup> are each hydrogen. In some embodiments of formula (II) or (IIa), R<com:Sup>23< / com:Sup> and R<com:Sup>23b< / com:Sup> are each hydrogen and R<com:Sup>23a< / com:Sup> is halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy. In some embodiments of formula (II) or (IIa), R<com:Sup>23< / com:Sup> and R<com:Sup>23b< / com:Sup> are each hydrogen and <com:Math><semantics>R23a<annotation encoding="application / x-tex">R^{23a}< / annotation>< / semantics>< / com:Math> is fluoro, methyl, or methoxy.

[0163] With reference to formula (II) or (IIa), in some embodiments, R<com:Sup>1< / com:Sup> is -OR<com:Sup>4< / com:Sup>, -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup>, or <com:Math><semantics>−N(OR5b)R5a<annotation encoding="application / x-tex">-N(OR^{5b})R^{5a}< / annotation>< / semantics>< / com:Math>.

[0164] In some embodiments of formula (II) or (IIa), R<com:Sup>1< / com:Sup> is -OR<com:Sup>4< / com:Sup>. In some embodiments, R<com:Sup>4< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> and each <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl- C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R4 is C1-C6 hydroxyalkyl. In some embodiments, R4 is C1-C6 alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl- 1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or <com:Math><semantics>N−C1−C6<annotation encoding="application / x-tex">N-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl hydroxyamino. In some embodiments, <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>R7−C(O)−C1−C6<annotation encoding="application / x-tex">R^7-C(O)-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydroxyamino.

[0165] In some embodiments of formula (II) or (IIa), R<com:Sup>1< / com:Sup> is selected from the group consisting of -OH, [Image disponible dans le document PDF, Image available in the PDF document]

[0166] In some embodiments of formula (II) or (IIa), R<com:Sup>1< / com:Sup> is -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup>. In some embodiments, R<com:Sup>5< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl- <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, or cyclobutyl-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl- 1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl hydroxyamino. In some embodiments, R<com:Sup>5< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydroxyamino.

[0167] In some embodiments of formula (II) or (IIa), R<com:Sup>5< / com:Sup> is selected from the group consisting of hydrogen, [Image disponible dans le document PDF, Image available in the PDF document]

[0168] In some embodiments of formula (II) or (IIa), R<com:Sup>1< / com:Sup> is -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup>. In some embodiments, R<com:Sup>5b< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R5b is C3-C8 cycloalkyl-C1-C6 alkyl, wherein the C3-C8 cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5b<annotation encoding="application / x-tex">R^{5b}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> hydroxyalkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R5b is C1-C6 alkylamino-C1-C6 alkyl. In some embodiments, R5b is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl- C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl-1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R5b is R7-C(O)-C1-C6 alkyl; and R7 is hydroxy, C1-C6 alkoxy, amino, C1-C6 alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl hydroxyamino. In some embodiments, R<com:Sup>5b< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydrox yamino.

[0169] In some embodiments of formula (II) or (IIa), R<com:Sup>1< / com:Sup> is -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup> and -OR<com:Sup>5b< / com:Sup> is selected from the group consisting of -OH, [Image disponible dans le document PDF, Image available in the PDF document]

[0170] In some embodiments of formula (II) or (IIa), R<com:Sup>5a< / com:Sup> is hydrogen. In some embodiments, <com:Math><semantics>R5a<annotation encoding="application / x-tex">R^{5a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5a<annotation encoding="application / x-tex">R^{5a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5a<annotation encoding="application / x-tex">R^{5a}< / annotation>< / semantics>< / com:Math> can be methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl. In some embodiments, R<com:Sup>5a< / com:Sup> is methyl.

[0171] With reference to formula (II) or (IIa), in some embodiments, R<com:Sup>1< / com:Sup> is a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, the N-linked heterocycloalkyl is N-linked azetidinyl, N-linked pyrrolidinyl, N-linked isoxazolidinyl, N-linked piperidinyl, or N-linked morpholinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked azetidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked pyrrolidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked isoxazolidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked piperidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked morpholinyl. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked azetidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R1 is N-linked pyrrolidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked piperidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked isoxazolidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked morpholinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein.

[0172] With reference to R<com:Sup>6< / com:Sup> as one or two substituents of the N-linked heterocycloalkyl in formula (II) or (IIa), in some embodiments, each R<com:Sup>6< / com:Sup> is independently hydroxyl, oxo, or amino. In some embodiments, each R<com:Sup>6< / com:Sup> is hydroxy. In some embodiments, each R<com:Sup>6< / com:Sup> is oxo. In some embodiments, each R<com:Sup>6< / com:Sup> is amino. In some embodiments, one of R<com:Sup>6< / com:Sup> is hydroxy and the other R<com:Sup>6< / com:Sup> is amino.

[0173] In some embodiments of formula (II) or (IIa), R<com:Sup>1< / com:Sup> is a N-linked heterocycloalkyl which is unsubstituted or substituted with hydroxyl, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked azetidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked pyrrolidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked piperidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked isoxazolidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked morpholinyl which is unsubstituted or substituted with hydroxy, oxo, or amino.

[0174] With reference to formulae (II) or (Ila), in some embodiments, R<com:Sup>2< / com:Sup> is halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is halo or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is halo,-CH<com:Sub>3< / com:Sub>, -SCH<com:Sub>3< / com:Sub>, C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkynyl.

[0175] In some embodiments of formulae (II) or (IIa), R<com:Sup>2< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2< / com:Sup> is iodo. In some embodiments, R<com:Sup>2< / com:Sup> is chloro. In some embodiments, R<com:Sup>2< / com:Sup> is bromo.

[0176] In some embodiments of formulae (II) or (IIa), R<com:Sup>2< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is methyl.

[0177] In some embodiments of formulae (II) or (IIa), R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub>.

[0178] In some embodiments of formulae (II) or (IIa), R<com:Sup>2< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl. In some embodiments, R<com:Sup>2< / com:Sup> is cyclopropyl.

[0179] In some embodiments of formulae (II) or (IIa), R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>4< / com:Sub> alkenyl. In some embodiments, R<com:Sup>2< / com:Sup> is vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, or butadienyl. In some embodiments, R<com:Sup>2< / com:Sup> is vinyl.

[0180] In some embodiments of formulae (II) or (IIa), R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl or propynyl. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl.

[0181] With reference to formulae (II) or (IIa), in some embodiments, R<com:Sup>2a< / com:Sup> is halo or C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl. In some embodiments, R<com:Sup>2a< / com:Sup> is halo or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is fluoro or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is iodo or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is chloro or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is bromo or CH<com:Sub>3< / com:Sub>.

[0182] In some embodiments of formulae (II) or (IIa), R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2a< / com:Sup> is iodo. In some embodiments, R<com:Sup>2a< / com:Sup> is chloro. In some embodiments, R<com:Sup>2a< / com:Sup> is bromo.

[0183] In some embodiments of formulae (II) or (IIa), R<com:Sup>2a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl. In some embodiments, R<com:Sup>2a< / com:Sup> is CH<com:Sub>3< / com:Sub>.

[0184] With reference to formulae (II) or (IIa), in some embodiments, R<com:Sup>2< / com:Sup> and R<com:Sup>2a< / com:Sup> are each halo. In some embodiments, R<com:Sup>2< / com:Sup> is halo and R<com:Sup>2a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is cyclopropyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> and R<com:Sup>2a< / com:Sup> are each independently fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2< / com:Sup> is halo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is bromo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is <com:Math><semantics>−SCH3<annotation encoding="application / x-tex">-SCH_3< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is fluoro. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is acetylenyl and <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is fluoro.

[0185] In some embodiments, the compound of formula (II) or formula (IIa) is represented by any one of the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] wherein R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>23< / com:Sup>, R<com:Sup>23a< / com:Sup>, and R<com:Sup>23b< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0186] In some embodiments of the above structures having formula (II) or (IIa), R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is methyl. In some embodiments of the above structures, R2 is acetylenyl and R2a is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is methyl. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is methyl.

[0187] In some embodiments of the above structures having formula (II) or (IIa), R<com:Sup>23< / com:Sup>, R<com:Sup>23a< / com:Sup>, and R<com:Sup>23b< / com:Sup> are each hydrogen. In some embodiments of the above structures, R<com:Sup>23< / com:Sup> and R<com:Sup>23b< / com:Sup> are each hydrogen and R<com:Sup>23a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>23< / com:Sup> and R<com:Sup>23b< / com:Sup> are each hydrogen and R<com:Sup>23a< / com:Sup> is methoxy.

[0188] In some embodiments, the compounds useful in the present methods are compounds of formula (III).

[0189] With reference to formula (III), in some embodiments, X<com:Sup>3< / com:Sup> is S and the compound is represented by formula (IIIa): [Image disponible dans le document PDF, Image available in the PDF document] (Illa), wherein R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0190] In some embodiments of formula (III), <com:Math><semantics>X3<annotation encoding="application / x-tex">X^3< / annotation>< / semantics>< / com:Math> is O and the compound is represented by formula (IIIb): [Image disponible dans le document PDF, Image available in the PDF document] (IIIb), wherein R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0191] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are each independently hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy.

[0192] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33< / com:Sup> is hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy. In some embodiments, R<com:Sup>33< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>33< / com:Sup> is halo. In some embodiments, R<com:Sup>33< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, <com:Math><semantics>R33<annotation encoding="application / x-tex">R^{33}< / annotation>< / semantics>< / com:Math> is fluoro. In some embodiments, <com:Math><semantics>R33<annotation encoding="application / x-tex">R^{33}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, R<com:Sup>33< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, <com:Math><semantics>R33<annotation encoding="application / x-tex">R^{33}< / annotation>< / semantics>< / com:Math> is methyl. In some embodiments, <com:Math><semantics>R33<annotation encoding="application / x-tex">R^{33}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy. In some embodiments, R<com:Sup>33< / com:Sup> is methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, or hexoxy. In some embodiments, R<com:Sup>33< / com:Sup> is methoxy.

[0193] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33a< / com:Sup> is hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy. In some embodiments, R<com:Sup>33a< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>33a< / com:Sup> is halo. In some embodiments, R<com:Sup>33a< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>33a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>33a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>33a< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>33a< / com:Sup> is methyl. In some embodiments, R<com:Sup>33a< / com:Sup> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy. In some embodiments, <com:Math><semantics>R33a<annotation encoding="application / x-tex">R^{33a}< / annotation>< / semantics>< / com:Math> is methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, or hexoxy. In some embodiments, R<com:Sup>33a< / com:Sup> is methoxy.

[0194] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33b< / com:Sup> is hydrogen, halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy. In some embodiments, R<com:Sup>33b< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>33b< / com:Sup> is halo. In some embodiments, R<com:Sup>33b< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>33b< / com:Sup> is fluoro. In some embodiments, R<com:Sup>33b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>33b< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>33b< / com:Sup> is methyl. In some embodiments, R<com:Sup>33b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy. In some embodiments, R<com:Sup>33b< / com:Sup> is methoxy, ethoxy, propoxy, iso-propoxy, butoxy, 2-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentoxy, or hexoxy. In some embodiments, R<com:Sup>33b< / com:Sup> is methoxy.

[0195] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are each hydrogen. In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33a< / com:Sup> and R<com:Sup>33b< / com:Sup> are each hydrogen and R<com:Sup>33< / com:Sup> is halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy. In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33< / com:Sup> and R<com:Sup>33b< / com:Sup> are each hydrogen and R<com:Sup>33a< / com:Sup> is fluoro, methyl, or methoxy. In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33< / com:Sup> and <com:Math><semantics>R33a<annotation encoding="application / x-tex">R^{33a}< / annotation>< / semantics>< / com:Math> are each hydrogen and <com:Math><semantics>R33b<annotation encoding="application / x-tex">R^{33b}< / annotation>< / semantics>< / com:Math> is halo, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy. In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33a< / com:Sup> and R<com:Sup>33b< / com:Sup> are each hydrogen and R<com:Sup>33< / com:Sup> is fluoro, methyl, or methoxy. In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33< / com:Sup> and R<com:Sup>33b< / com:Sup> are each hydrogen and R<com:Sup>33a< / com:Sup> is fluoro, methyl, or methoxy. In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33< / com:Sup> and R<com:Sup>33a< / com:Sup> are each hydrogen and R<com:Sup>33b< / com:Sup> is fluoro, methyl, or methoxy.

[0196] With reference to any one of formulae (III), (IIIa), and (IIIb), in some embodiments, R<com:Sup>1< / com:Sup> is <com:Math><semantics>−OR4<annotation encoding="application / x-tex">-OR^4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5R5a<annotation encoding="application / x-tex">-NR^5R^{5a}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−N(OR5b)R5a<annotation encoding="application / x-tex">-N(OR^{5b})R^{5a}< / annotation>< / semantics>< / com:Math>.

[0197] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>1< / com:Sup> is -OR<com:Sup>4< / com:Sup>. In some embodiments, R<com:Sup>4< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> hydroxyalkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl-1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl hydroxyamino. In some embodiments, R<com:Sup>4< / com:Sup> is <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydroxyamino.

[0198] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>1< / com:Sup> is selected from the group consisting of -OH, [Image disponible dans le document PDF, Image available in the PDF document]

[0199] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>1< / com:Sup> is -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup>. In some embodiments, R<com:Sup>5< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> hydroxyalkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl-1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl hydroxyamino. In some embodiments, R<com:Sup>5< / com:Sup> is <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydroxyamino.

[0200] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>5< / com:Sup> is selected from the group consisting of hydrogen, [Image disponible dans le document PDF, Image available in the PDF document]

[0201] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>1< / com:Sup> is -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup>. In some embodiments, R<com:Sup>5b< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is as defined and described herein. In some embodiments, R5b is C3-C8 cycloalkyl-C1-C6 alkyl, wherein the C3-C8 cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5b<annotation encoding="application / x-tex">R^{5b}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> hydroxyalkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R5b is heterocycloalkyl unsubstituted or substituted with one to six R6 and each R6 is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5b<annotation encoding="application / x-tex">R^{5b}< / annotation>< / semantics>< / com:Math> is heterocycloalkyl-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5b<annotation encoding="application / x-tex">R^{5b}< / annotation>< / semantics>< / com:Math> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl- C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl-1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl hydroxyamino. In some embodiments, R5b is R7-C(O)-C1-C6 alkyl; and R7 is hydroxy, C1-C6 alkoxy, amino, or hydroxyamino.

[0202] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>1< / com:Sup> is -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup> and -OR<com:Sup>5b< / com:Sup> is selected from the group consisting of -OH, [Image disponible dans le document PDF, Image available in the PDF document]

[0203] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>5a< / com:Sup> is hydrogen. In some embodiments, <com:Math><semantics>R5a<annotation encoding="application / x-tex">R^{5a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5a<annotation encoding="application / x-tex">R^{5a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, R<com:Sup>5a< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl. In some embodiments, R<com:Sup>5a< / com:Sup> is methyl.

[0204] With reference to any one of formulae (III), (IIIa), and (IIIb), in some embodiments, R<com:Sup>1< / com:Sup> is a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, the N-linked heterocycloalkyl is N-linked azetidinyl, N-linked pyrrolidinyl, N-linked isoxazolidinyl, N-linked piperidinyl, or N-linked morpholinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked azetidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked pyrrolidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked isoxazolidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked piperidinyl. In some embodiments, the N-linked heterocycloalkyl is N-linked morpholinyl. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked azetidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked pyrrolidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked piperidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked isoxazolidinyl which is unsubstituted or substituted with one or two R<com:Sup>6< / com:Sup>, wherein R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked morpholinyl which is unsubstituted or substituted with one or two <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, wherein <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is as defined and described herein.

[0205] With reference to R<com:Sup>6< / com:Sup> as one or two substituents of the N-linked heterocycloalkyl in any one of formulae (III), (IIIa), and (IIIb), in some embodiments, each R<com:Sup>6< / com:Sup> is independently hydroxy, oxo, or amino. In some embodiments, each R<com:Sup>6< / com:Sup> is hydroxy. In some embodiments, each R<com:Sup>6< / com:Sup> is oxo. In some embodiments, each R<com:Sup>6< / com:Sup> is amino. In some embodiments, one of R<com:Sup>6< / com:Sup> is hydroxy and the other R<com:Sup>6< / com:Sup> is amino.

[0206] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R1 is a N-linked heterocycloalkyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked azetidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked pyrrolidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked piperidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked isoxazolidinyl which is unsubstituted or substituted with hydroxy, oxo, or amino. In some embodiments, R<com:Sup>1< / com:Sup> is N-linked morpholinyl which is unsubstituted or substituted with hydroxy, oxo, or amino.

[0207] With reference to any one of formulae (III), (IIIa), and (IIIb), in some embodiments, R<com:Sup>2< / com:Sup> is halo, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl, C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is halo or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is halo,-CH<com:Sub>3< / com:Sub>, -SCH<com:Sub>3< / com:Sub>, C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkenyl, or C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkynyl.

[0208] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2< / com:Sup> is iodo. In some embodiments, R<com:Sup>2< / com:Sup> is chloro. In some embodiments, R<com:Sup>2< / com:Sup> is bromo.

[0209] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is methyl.

[0210] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub>.

[0211] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl. In some embodiments, R<com:Sup>2< / com:Sup> is cyclopropyl.

[0212] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>4< / com:Sub> alkenyl. In some embodiments, R<com:Sup>2< / com:Sup> is vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, or butadienyl. In some embodiments, R<com:Sup>2< / com:Sup> is vinyl.

[0213] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> alkynyl. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl or propynyl. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl.

[0214] With reference to any one of formulae (III), (IIIa), and (IIIb), in some embodiments, R<com:Sup>2a< / com:Sup> is halo or C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl. In some embodiments, R<com:Sup>2a< / com:Sup> is halo or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is fluoro or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is iodo or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is chloro or CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2a< / com:Sup> is bromo or CH<com:Sub>3< / com:Sub>.

[0215] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2a< / com:Sup> is iodo. In some embodiments, R<com:Sup>2a< / com:Sup> is chloro. In some embodiments, <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is bromo.

[0216] In some embodiments of any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2a< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CH3<annotation encoding="application / x-tex">CH_3< / annotation>< / semantics>< / com:Math>.

[0217] With reference to any one of formulae (III), (IIIa), and (IIIb), in some embodiments, R<com:Sup>2< / com:Sup> and <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> are each halo. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is halo and <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is -S-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl and <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is halo. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>−SCH3<annotation encoding="application / x-tex">-SCH_3< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is halo. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math> cycloalkyl and <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is halo. In some embodiments, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is cyclopropyl and <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkenyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is C<com:Sub>2< / com:Sub>-C<com:Sub>6< / com:Sub> alkynyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is halo. In some embodiments, R<com:Sup>2< / com:Sup> and R<com:Sup>2a< / com:Sup> are each independently fluoro, chloro, bromo, or iodo. In some embodiments, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2< / com:Sup> is halo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is bromo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is -CH<com:Sub>3< / com:Sub>. In some embodiments, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is fluoro.

[0218] In some embodiments, the compound of formula (III) is represented by any one of the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] wherein X<com:Sup>3< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0219] In some embodiments of the above structures having any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is iodo and R<com:Sup>2a< / com:Sup> is methyl. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is acetylenyl and R<com:Sup>2a< / com:Sup> is methyl. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>2< / com:Sup> is -SCH<com:Sub>3< / com:Sub> and R<com:Sup>2a< / com:Sup> is methyl.

[0220] In some embodiments of the above structures having any one of formulae (III), (IIIa), and (IIIb), R<com:Sup>33< / com:Sup>, R<com:Sup>33a< / com:Sup>, and R<com:Sup>33b< / com:Sup> are each hydrogen. In some embodiments of the above structures, R<com:Sup>33< / com:Sup> and R<com:Sup>33b< / com:Sup> are each hydrogen and R<com:Sup>33a< / com:Sup> is fluoro. In some embodiments of the above structures, R<com:Sup>33< / com:Sup> and R<com:Sup>33b< / com:Sup> are each hydrogen and R<com:Sup>33a< / com:Sup> is methyl. In some embodiments of the above structures, R<com:Sup>33< / com:Sup> and R<com:Sup>33b< / com:Sup> are each hydrogen and R<com:Sup>33a< / com:Sup> is methoxy. In some embodiments of the above structures, R<com:Sup>33< / com:Sup> and R<com:Sup>33a< / com:Sup> are each hydrogen and R<com:Sup>33b< / com:Sup> is methyl. In some embodiments of the above structures, R<com:Sup>33< / com:Sup> and R<com:Sup>33a< / com:Sup> are each hydrogen and R<com:Sup>33b< / com:Sup> is methoxy. In some embodiments of the above structures, R<com:Sup>33a< / com:Sup> and R<com:Sup>33b< / com:Sup> are each hydrogen and R<com:Sup>33< / com:Sup> is methyl.

[0221] In some embodiments, the compounds useful in the present methods are compounds of formula (IV).

[0222] With reference to formula (IV), in some embodiments, R<com:Sup>43< / com:Sup> is cyano, -C(O)NR<com:Sup>48< / com:Sup>R<com:Sup>48a< / com:Sup>, or -C(O)R<com:Sup>46< / com:Sup>, and R<com:Sup>43a< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>43a< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>43a< / com:Sup> is halo. In some embodiments, R<com:Sup>43a< / com:Sup> is fluoro, chloro, bromo, or iodo. In some embodiments, <com:Math><semantics>R43a<annotation encoding="application / x-tex">R^{43a}< / annotation>< / semantics>< / com:Math> is fluoro. In some embodiments, <com:Math><semantics>R43a<annotation encoding="application / x-tex">R^{43a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, R<com:Sup>43a< / com:Sup> is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl. In some embodiments, R<com:Sup>43a< / com:Sup> is methyl.

[0223] In some embodiments of formula (IV), R<com:Sup>43< / com:Sup> is cyano and the compound is represented by formula (IVa): [Image disponible dans le document PDF, Image available in the PDF document] (IVa), wherein R<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, and R<com:Sup>43a< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0224] In some embodiments of formula (IVa), R<com:Sup>43a< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>43a< / com:Sup> is hydrogen, halo, or methyl. In some embodiments, R<com:Sup>43a< / com:Sup> is methyl.

[0225] With reference to formula (IV), in some embodiments, R<com:Sup>43< / com:Sup> is -C(O)NR<com:Sup>48< / com:Sup>R<com:Sup>48a< / com:Sup> and the compound is represented by formula (IVb): [Image disponible dans le document PDF, Image available in the PDF document] (IVb), wherein R<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>43a< / com:Sup>, R<com:Sup>48< / com:Sup>, and R<com:Sup>48a< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0226] In some embodiments of formula (IVb), R<com:Sup>43a< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>43a< / com:Sup> is hydrogen, halo, or methyl. In some embodiments, R<com:Sup>43a< / com:Sup> is methyl.

[0227] In some embodiments of formula (IVb), R<com:Sup>48< / com:Sup> and R<com:Sup>48a< / com:Sup> are each independently hydrogen or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>48< / com:Sup> and R<com:Sup>48a< / com:Sup> are each hydrogen. In some embodiments, R<com:Sup>48< / com:Sup> and R<com:Sup>48a< / com:Sup> are each independently C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, one of R<com:Sup>48< / com:Sup> and R<com:Sup>48a< / com:Sup> is hydrogen and the other is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl.

[0228] In some embodiments of formula (IV), R<com:Sup>43< / com:Sup> is -C(O)NH<com:Sub>2< / com:Sub>, and R<com:Sup>43a< / com:Sup> is methyl.

[0229] With reference to formula (IV), in some embodiments, R<com:Sup>43< / com:Sup> is -C(O)R<com:Sup>46< / com:Sup>, and the compound is represented by formula (IVc): [Image disponible dans le document PDF, Image available in the PDF document] (IVc), wherein R<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>43a< / com:Sup>, and R<com:Sup>46< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0230] In some embodiments of formula (IVc), R<com:Sup>43a< / com:Sup> is hydrogen, halo, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>43a< / com:Sup> is hydrogen, halo, or methyl. In some embodiments, R<com:Sup>43a< / com:Sup> is methyl.

[0231] In some embodiments of formula (IVc), R<com:Sup>46< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl. In some embodiments, R<com:Sup>46< / com:Sup> is hydrogen, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl, wherein the haloalkyl is alkyl substituted with 1, 2, or 3 fluoro.

[0232] In some embodiments of formula (IVc), R<com:Sup>46< / com:Sup> is hydrogen. In some embodiments of formula (IVc), R<com:Sup>46< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>46< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl. In some embodiments, R<com:Sup>6< / com:Sup> is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or t-butyl.

[0233] In some embodiments of formula (IVc), R<com:Sup>46< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> haloalkyl wherein the haloalkyl is alkyl substituted with 1, 2, or 3 fluoro. In some embodiments, R<com:Sup>46< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> haloalkyl wherein the C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> haloalkyl is C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub> alkyl substituted with 1, 2, or 3 fluoro. In some embodiments, R<com:Sup>46< / com:Sup> is trifluoromethyl, fluoromethyl, or 2,2,2-trifluoroethyl.

[0234] In some embodiments of formula (IVc), R<com:Sup>46< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl or heterocycloalkyl. In some embodiments, R<com:Sup>46< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl. In some embodiments, R<com:Sup>46< / com:Sup> is cyclopropyl or cyclobutyl. In some embodiments, R<com:Sup>6< / com:Sup> is heterocycloalkyl. In some embodiments, R<com:Sup>46< / com:Sup> is a 3 to 8 membered heterocycloalkyl having 1 to 3 heteroatoms of N, O, or S. In some embodiments, R<com:Sup>46< / com:Sup> is a 3 to 6 membered heterocycloalkyl having 1 to 2 heteroatoms of N or O. In some embodiments, R<com:Sup>46< / com:Sup> is aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, isoxazolidinyl, or morpholinyl.

[0235] Returning to formula (IV), in some embodiments, R<com:Sup>43< / com:Sup> and R<com:Sup>43a< / com:Sup> together form -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)- or -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)-, each of which is unsubstituted or substituted with one or two R<com:Sup>49< / com:Sup>. In some embodiments, R<com:Sup>43< / com:Sup> and R<com:Sup>43a< / com:Sup> together form -CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>C(O)- or <com:Math><semantics>−CH2CH2CH2C(O)−.<annotation encoding="application / x-tex">-CH_2CH_2CH_2C(O)-.< / annotation>< / semantics>< / com:Math>

[0236] In some embodiments of formula (IV), the compound is represented by formula (IVd-1) or (IVd-2): [Image disponible dans le document PDF, Image available in the PDF document] wherein R<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, and R<com:Sup>49< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0237] In some embodiments of formula (IV), the compound is represented by formula (IVe-1) or (IVe-2): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (IVe-1) or <com:Math><semantics>(IVe−2),<annotation encoding="application / x-tex">(IVe-2),< / annotation>< / semantics>< / com:Math> wherein R<com:Sup>1< / com:Sup>, R<com:Sup>2< / com:Sup>, R<com:Sup>2a< / com:Sup>, and R<com:Sup>49< / com:Sup> are as defined herein in any aspect or embodiment described herein.

[0238] In some embodiments of any one of formulae (IVd-1), (IVd-2), (IVe-1), and (IVe-2), each <com:Math><semantics>R49<annotation encoding="application / x-tex">R^{49}< / annotation>< / semantics>< / com:Math> is independently <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments of any one of formulae (IVd-1), (IVd-2), (IVe-1), and (IVe-2), R<com:Sup>49< / com:Sup> is absent.

[0239] With reference to any one of formulae (IV), (IVa), (IVb), (IVc), (IVd-1), (IVd-2), (IVe-1) and (IVe-2), in some embodiments, R<com:Sup>1< / com:Sup> is -OR<com:Sup>4< / com:Sup>, -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup>, or -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup>.

[0240] In some embodiments of any one of formulae (IV), (IVa), (IVb), (IVc), (IVd-1), (IVd-2), (IVe-1) and (IVe-2), R<com:Sup>1< / com:Sup> is -OR<com:Sup>4< / com:Sup>. In some embodiments, R<com:Sup>4< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino- C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>4< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R4 is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C1-C6 alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2-dimethyl- 1,3-dioxolan-4-yl-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino, di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino, hydroxyamino, or <com:Math><semantics>N−C1−C6<annotation encoding="application / x-tex">N-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl hydroxyamino. In some embodiments, <com:Math><semantics>R4<annotation encoding="application / x-tex">R^4< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>R7−C(O)−C1−C6<annotation encoding="application / x-tex">R^7-C(O)-C_1-C_6< / annotation>< / semantics>< / com:Math> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydroxyamino.

[0241] In some embodiments of any one of formulae (IV), (IVa), (IVb), (IVc), (IVd-1), (IVd-2), (IVe-1) and (IVe-2), R1 is selected from the group consisting of -OH, [Image disponible dans le document PDF, Image available in the PDF document]

[0242] In some embodiments of any one of formulae (IV), (IVa), (IVb), (IVc), (IVd-1), (IVd-2), (IVe-1) and (IVe-2), R<com:Sup>1< / com:Sup> is -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup>. In some embodiments, R<com:Sup>5< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C3-C8 cycloalkyl group is unsubstituted or substituted with one to six R6 and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> hydroxyalkyl. In some embodiments, <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino- C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> and each <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5< / com:Sup> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, 2,2-dimethyl-1,3- dioxolan-4-yl-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl; and <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is hydroxy, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkoxy, amino, <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkylamino, di-<com:Math><semantics>(C1<annotation encoding="application / x-tex">(C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl)amino, hydroxyamino, or <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl hydroxyamino. In some embodiments, R<com:Sup>5< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and R<com:Sup>7< / com:Sup> is hydroxy, C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy, amino, or hydroxyamino.

[0243] In some embodiments of any one of formulae (IV), (IVa), (IVb), (IVc), (IVd-1), (IVd-2), (IVe-1) and (IVe-2), R<com:Sup>1< / com:Sup> is -NR<com:Sup>5< / com:Sup>R<com:Sup>5a< / com:Sup> and R<com:Sup>5< / com:Sup> is selected from the group consisting of hydrogen, [Image disponible dans le document PDF, Image available in the PDF document]

[0244] In some embodiments of any one of formulae (IV), (IVa), (IVb), (IVc), (IVd-1), (IVd-2), (IVe-1) and (IVe-2), R<com:Sup>1< / com:Sup> is -N(OR<com:Sup>5b< / com:Sup>)R<com:Sup>5a< / com:Sup>. In some embodiments, R<com:Sup>5b< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R5b is C3-C8 cycloalkyl unsubstituted or substituted with one to six R6 and each R6 is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the C<com:Sub>3< / com:Sub>-C<com:Sub>8< / com:Sub> cycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is cyclopropyl, cyclobutyl, cyclopropyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or cyclobutyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, each of the cyclopropyl and cyclobutyl groups is unsubstituted or substituted with one to six <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> and each <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> is independently hydroxy or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> hydroxyalkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkoxy-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkylamino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is di-(C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl)amino-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and R<com:Sup>6< / com:Sup> is as defined and described herein. In some embodiments, R<com:Sup>5b< / com:Sup> is heterocycloalkyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, wherein the heterocycloalkyl group is unsubstituted or substituted with one to six R<com:Sup>6< / com:Sup> and each R<com:Sup>6< / com:Sup> is independently hydroxy or C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, oxetanyl-C<com:Sub>1< / com:Sub>- C<com:Sub>6< / com:Sub> alkyl, azetidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, pyrrolidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, piperidinyl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl, or 2,2- dimethyl-1,3-dioxolan-4-yl-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl. In some embodiments, R<com:Sup>5b< / com:Sup> is R<com:Sup>7< / com:Sup>-C(O)-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; and <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is hydroxy, <com:Math><semantics>ℂ1<annotation encoding="application / x-tex">\mathbb{C}_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>ℂ6<annotation encoding="application / x-tex">\mathbb{C}_6< / annotation>< / semantics>< / com:Math> alkoxy, amino, <com:Math><semantics>ℂ1<annotation encoding="application / x-tex">\mathbb{C}_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>ℂ6<annotation encoding="application / x-tex">\mathbb{C}_6< / annotation>< / semantics>< / com:Math> alkylamino, di-<com:Math><semantics>(ℂ1<annotation encoding="application / x-tex">(\mathbb{C}_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>ℂ6<annotation encoding="application / x-tex">\mathbb{C}_6< / annotation>< / semantics>< / com:Math> alkyl)amino, hydroxyamino, or N-C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl hydroxyamino. In some embodiments, R...

Claims

1. A compound for use in treating a birthmark, or for use in manufacture of a medicament for treating the birthmark, wherein the compound is represented by formula (IV): [Image disponible dans le document PDF, Image available in the PDF document] (IV), or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein: R 1 is -OR 4 , -NR 5 R 5a , -N(OR 5b )R 5a , or a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R 6 ; R 2 R^2 is halo, C 1 C_1 - C 6 C_6 alkyl, -S- C 1 C_1 - C 6 C_6 alkyl, C 3 C_3 - C 8 C_8 cycloalkyl, C 2 C_2 - C 6 C_6 alkenyl, or C 2 C_2 - C 6 C_6 alkynyl; R 2 a R^{2a} is halo or C 1 C_1 - C 6 C_6 alkyl; R 4 , R 5 , and R 5b are each independently hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, amino-C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl, heterocycloalkyl, heterocycloalkyl-C 1 -C 6 alkyl, or R 7 -C(O)-C 1 -C 6 alkyl, wherein each of the C 3 -C 8 cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six R 6 R^6 ; R 5a is hydrogen or C 1 -C 6 alkyl; each R 6 is independently halo, hydroxy, oxo, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 haloalkyl, amino, C 1 -C 6 alkylamino, di-(C 1 -C 6 alkyl)amino, amino-C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, or di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl; R 7 R^7 is hydroxy, C 1 C_1 - C 6 C_6 alkoxy, amino, C 1 C_1 - C 6 C_6 alkylamino, di- ( C 1 (C_1 - C 6 C_6 alkyl)amino, hydroxyamino, or N-C 1 -C 6 alkyl hydroxyamino; R 43 and R 43a together form -CH 2 CH 2 C(O)- or -CH 2 CH 2 C(O)-, each of which is unsubstituted or substituted with one or two R 49 ; or R 43 R^{43} is cyano, − C ( O ) N R 48 R 48 a -C(O)NR^{48}R^{48a} , or − C ( O ) R 46 -C(O)R^{46} ; R 43a is hydrogen, halo, or C 1 -C 6 alkyl; R 46 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl or heterocycloalkyl; R 48 and R 48a are independently hydrogen or C 1 -C 6 alkyl; and each R 49 is independently C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, or C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl.

2. A use of a compound for treating a birthmark, wherein the compound is represented by formula (IV): [Image disponible dans le document PDF, Image available in the PDF document] (IV), or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein: R 1 is -OR 4 , -NR 5 R 5a , -N(OR 5b )R 5a , or a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R 6 ; R 2 R^2 is halo, C 1 C_1 - C 6 C_6 alkyl, -S- C 1 C_1 - C 6 C_6 alkyl, C 3 C_3 - C 8 C_8 cycloalkyl, C 2 C_2 - C 6 C_6 alkenyl, or C 2 C_2 - C 6 C_6 alkynyl; R 2 a R^{2a} is halo or C 1 C_1 - C 6 C_6 alkyl; R 4 , R 5 , and R 5b are each independently hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, amino-C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl, heterocycloalkyl, heterocycloalkyl-C 1 -C 6 alkyl, or R 7 -C(O)-C 1 -C 6 alkyl, wherein each of the C 3 -C 8 cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six R 6 R^6 ; R 5 a R^{5a} is hydrogen or C 1 C_1 - C 6 C_6 alkyl; each R 6 is independently halo, hydroxy, oxo, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 haloalkyl, amino, C 1 -C 6 alkylamino, di-(C 1 -C 6 alkyl)amino, amino-C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, or di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl; R 7 R^7 is hydroxy, C 1 C_1 - C 6 C_6 alkoxy, amino, C 1 C_1 - C 6 C_6 alkylamino, di- ( C 1 (C_1 - C 6 C_6 alkyl)amino, hydroxyamino, or N-C 1 -C 6 alkyl hydroxyamino; R 43 and R 43a together form -CH 2 CH 2 C(O)- or -CH 2 CH 2 C(O)-, each of which is unsubstituted or substituted with one or two R 49 ; or R 43 R^{43} is cyano, − C ( O ) N R 48 R 48 a -C(O)NR^{48}R^{48a} , or − C ( O ) R 46 -C(O)R^{46} ; R 43 a R^{43a} is hydrogen, halo, or C 1 C_1 - C 6 C_6 alkyl; R 46 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl or heterocycloalkyl; R 48 and R 48a are independently hydrogen or C 1 -C 6 alkyl; and each R 49 is independently C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, or C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl.

3. Use of a compound in the manufacture of a medicament for the treatment of a birthmark, wherein the compound is represented by formula (IV): [Image disponible dans le document PDF, Image available in the PDF document] (IV), or a stereoisomer, a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein: R 1 is -OR 4 , -NR 5 R 5a , -N(OR 5b )R 5a , or a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R 6 R^6 ; R 2 R^2 is halo, C 1 C_1 - C 6 C_6 alkyl, -S- C 1 C_1 - C 6 C_6 alkyl, C 3 C_3 - C 8 C_8 cycloalkyl, C 2 C_2 - C 6 C_6 alkenyl, or C 2 C_2 - C 6 C_6 alkynyl; R 2 a R^{2a} is halo or C 1 C_1 - C 6 C_6 alkyl; R 4 , R 5 , and R 5b are each independently hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, amino-C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl, heterocycloalkyl, heterocycloalkyl-C 1 -C 6 alkyl, or R 7 -C(O)-C 1 -C 6 alkyl, wherein each of the C 3 -C 8 cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six R 6 R^6 ; R 5 a R^{5a} is hydrogen or C 1 C_1 - C 6 C_6 alkyl; each R 6 is independently halo, hydroxy, oxo, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 -hydroxyalkyl, C 1 -C 6 haloalkyl, amino, C 1 -C 6 alkylamino, di-(C 1 -C 6 alkyl)amino, amino-C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, or di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl; R 7 R^7 is hydroxy, C 1 C_1 - C 6 C_6 alkoxy, amino, C 1 C_1 - C 6 C_6 alkylamino, di- ( C 1 (C_1 - C 6 C_6 alkyl)amino, hydroxyamino, or N-C 1 -C 6 alkyl hydroxyamino; R 43 and R 43a together form -CH 2 CH 2 C(O)- or -CH 2 CH 2 C(O)-, each of which is unsubstituted or substituted with one or two R 49 ; or R 43 R^{43} is cyano, − C ( O ) N R 48 R 48 a -C(O)NR^{48}R^{48a} , or − C ( O ) R 46 -C(O)R^{46} ; R 43 a R^{43a} is hydrogen, halo, or C 1 C_1 - C 6 C_6 alkyl; R 46 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl or heterocycloalkyl; R 48 and R 48a are independently hydrogen or C 1 -C 6 alkyl; and each R 49 is independently C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, or C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl.

4. The compound for use of claim 1, or the use of claim 2 or 3, wherein the compound has the formula selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]5. The compound for use of claim 1 or 4, or the use of any one of claims 2-4, wherein R 48 R^{48} and R 48 a R^{48a} are hydrogen.

6. The compound for use of claim 1 or 4, or the use of any one of claims 2-4, wherein R 46 R^{46} is hydrogen, C 1 C_1 - C 6 C_6 alkyl, or C 1 C_1 - C 6 C_6 haloalkyl.

7. The compound for use of any one of claims 1, 4, and 6, or the use of any one of claims 2-4 and 6, wherein R 46 R^{46} is C 1 C_1 - C 6 C_6 alkyl.

8. The compound for use of any one of claims 1, 4, 6, and 7, or the use of any one of claims 2-4, 6, and 7, wherein R 46 is methyl, ethyl, propyl, or butyl.

9. The compound for use of any one of claims 1 and 4-8, or the use of any one of claims 2-8, wherein R 43 a R^{43a} is hydrogen.

10. The compound for use of any one of claims 1 and 4-8 or the use of any one of claims 2-8, wherein R 43 a R^{43a} is halo.

11. The compound for use of any one of claims 1 and 4-8, or the use of any one of claims 2-8, wherein R 43 a R^{43a} is C 1 C_1 - C 6 C_6 alkyl.

12. The compound for use of any one of claims 1, 4-8 and 11, or the use of any one of claims 2-8 and 11, wherein R 43 a R^{43a} is methyl.

13. The compound for use of claim 1 or 4, or the use of any one of claims 2-4, wherein each R 49 R^{49} is independently C 1 C_1 - C 6 C_6 alkyl.

14. The compound for use of claim 1 or 4, or the use of any one of claims 2-4, wherein R 49 R^{49} is absent.

15. The compound for use of any one of claims 1 and 4-14, or the use of any one of claims 2-14, wherein R 1 R^1 is − O R 4 -OR^4 , − N R 5 R 5 a -NR^5R^{5a} , or − N ( O R 5 b ) R 5 a -N(OR^{5b})R^{5a} .

16. The compound for use of any one of claims 1 and 4-15, or the use of any one of claims 2-15, wherein R 1 is -OR 4 ; R 4 is hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, amino-C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl, heterocycloalkyl, heterocycloalkyl C 1 -C 6 alkyl, or R 7 -C(O)-C 1 -C 6 alkyl; R 7 is hydroxy, C 1 -C 6 alkoxy, amino, or hydroxyamino; and each of the C 3 -C 8 cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six R 6 R^6 and each R 6 R^6 is independently hydroxy or C 1 C_1 - C 6 C_6 alkyl.

17. The compound for use of any one of claims 1 and 4-16, or the use of any one of claims 2-16, wherein R 1 is selected from the group consisting of –OH, [Image disponible dans le document PDF, Image available in the PDF document]18. The compound for use of any one of claims 1 and 4-15, or the use of any one of claims 2-15, wherein R 1 is -NR 5 R 5a ; R 5 is hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, amino-C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl, heterocycloalkyl, C 1 C_1 - C 6 C_6 alkyl, or R 7 R^7 - C ( O ) C(O) - C 1 C_1 - C 6 C_6 alkyl; R 7 R^7 is hydroxy, C 1 C_1 - C 6 C_6 alkoxy, amino, or hydroxyamino; and each of the C 3 -C 8 cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six R 6 R^6 and each R 6 R^6 is independently hydroxy or C 1 C_1 - C 6 C_6 alkyl.

19. The compound for use of any one of claims 1, 4-15, and 18, or the use of any one of claims 2-15 and 18, wherein R 5 is selected from the group consisting of hydrogen, [Image disponible dans le document PDF, Image available in the PDF document]20. The compound for use of any one of claims 1 and 4-15, or the use of any one of claims 2-15, wherein R 1 is -NR 5 R 5a and R 5 is -OR 5b .

21. The compound for use of any one of claims 1, 4-15, and 20, or the use of any one of claims 2-15 and 20, wherein R 1 is -N(OR 5b )R 5a ; R 5b is hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy-C 1 -C 6 alkyl, amino- C 1 -C 6 alkyl, C 1 -C 6 alkylamino-C 1 -C 6 alkyl, di-(C 1 -C 6 alkyl)amino-C 1 -C 6 alkyl, heterocycloalkyl, heterocycloalkyl-C 1 -C 6 alkyl, or R 7 -C(O)-C 1 -C 6 alkyl; R 7 is hydroxy, C 1 -C 6 alkoxy, amino, or hydroxyamino; and each of the C 3 -C 8 cycloalkyl and heterocycloalkyl groups is unsubstituted or substituted with one to six R 6 R^6 and each R 6 R^6 is independently hydroxy or C 1 C_1 - C 6 C_6 alkyl.

22. The compound for use of any one of claims 1, 4-15, 20, and 21, or the use of any one of claims 2-15, 20, and 21, wherein -OR 5b is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document]23. The compound for use of any one of claims 1, 4-15, and 18-22, or the use of any one of claims 2-15 and 18-22, wherein R 5a is hydrogen.

24. The compound for use of any one of claims 1, 4-15, and 18-22, or the use of any one of claims 2-15 and 18-22, wherein R 5 a R^{5a} is C 1 C_1 - C 6 C_6 alkyl.

25. The compound for use of any one of claims 1 and 4-14, or the use of any one of claims 2-14, wherein R 1 is a N-linked heterocycloalkyl which is unsubstituted or substituted with one or two R 6 R^6 .

26. The compound for use of any one of claims 1, 4-14, and 25, or the use of any one of claims 2-14 and 25, wherein the N-linked heterocycloalkyl is N-linked azetidinyl, N-linked pyrrolidinyl, or N-linked isoxazolidinyl.

27. The compound for use of any one of claims 1, 4-14, 25, and 26, or the use of any one of claims 2-14 and 25-26, wherein each R 6 is independently hydroxyl, oxo, or amino.

28. The compound for use of any one of claims 1 and 4-27, or the use of any one of claims 2-27, wherein R 2 R^2 is halo, C 1 C_1 - C 6 C_6 alkyl, -S- C 1 C_1 - C 6 C_6 alkyl, or C 2 C_2 - C 6 C_6 alkynyl.

29. The compound for use of any one of claims 1 and 4-28, or the use of any one of claims 2 − 28 2-28 , wherein R 2 R^2 is halo.

30. The compound for use of any one of claims 1 and 4-29, or the use of any one of claims 2 − 29 2-29 , wherein R 2 R^2 is iodo.

31. The compound for use of any one of claims 1 and 4-28, or the use of any one of claims 2-28, wherein R 2 R^2 is C 1 C_1 - C 6 C_6 alkyl.

32. The compound for use of any one of claims 1, 4-28, and 31, or the use of any one of claims 2-28 and 31, wherein R 2 R^2 is C H 3 CH_3 .

33. The compound for use of any one of claims 1 and 4-28, or the use of any one of claims 2-28, wherein R 2 R^2 is -S- C 1 C_1 - C 6 C_6 alkyl.

34. The compound for use of any one of claims 1, 4-28, and 33, or the use of any one of claims 2-28 and 33, wherein R 2 R^2 is -SCH 3 .

35. The compound for use of any one of claims 1 and 4-28, or the use of any one of claims 2-28, wherein R 2 R^2 is C 2 C_2 - C 6 C_6 alkynyl.

36. The compound for use of any one of claims 1, 4-28, and 35, or the use of any one of claims 2 − 28 2-28 and 35 35 , wherein R 2 R^2 is acetylenyl.

37. The compound for use of any one of claims 1 and 4-36, or the use of any one of claims 2 − 36 2-36 , wherein R 2 a R^{2a} is halo.

38. The compound for use of any one of claims 1 and 4-37, or the use of any one of claims 2-37, wherein R 2 a R^{2a} is fluoro.

39. The compound for use of any one of claims 1 and 4-36, or the use of any one of claims 2-36, wherein R 2 a R^{2a} is C 1 C_1 - C 6 C_6 alkyl.

40. The compound for use of any one of claims 1, 4-36, and 39, or the use of any one of claims 2 − 36 2-36 and 39 39 , where R 2 a R^{2a} is methyl.

41. The compound for use of claim 1, or the use of claim 2 or 3, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , _ ~ ~ [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] - or a pharmaceutically acceptable salt thereof.

42. The compound for use of claim 1, or the use of claim 2 or 3, wherein the compound is represented by formula (IVe-1): [Image disponible dans le document PDF, Image available in the PDF document] (IVe-1), or a pharmaceutically acceptable salt thereof, wherein: [Image disponible dans le document PDF, Image available in the PDF document] R 2 is halo, C 1 -C 6 alkyl, -S-C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl; R 2 a R^{2a} is halo or C 1 C_1 - C 6 C_6 alkyl; R 5 and R 5b are each independently C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, or amino-C 1 -C 6 alkyl, wherein the C 3 -C 8 cycloalkyl group is unsubstituted; R 5a is hydrogen; and each R 49 R^{49} is independently C 1 C_1 - C 6 C_6 alkyl.

43. The compound for use of claim 42 or the use of claim 42, wherein R 1 is − N ( O R 5 b ) R 5 a -N(OR^{5b})R^{5a} ; and R 5 b R^{5b} is C 1 C_1 - C 6 C_6 hydroxyalkyl.

44. The compound for use of claim 42 42 or the use of claim 42 42 , wherein R 2 R^2 and R 2 a R^{2a} are each independently halo.

45. The compound for use of claim 42 or 44, or the use of claim 42 or 44, wherein R 2 R^2 is iodo; and R 2 a R^{2a} is fluoro.

46. The compound for use of claim 42 or the use of claim 42, wherein R 49 is absent.

47. The compound for use of claim 42 or the use of claim 42, wherein the compound is selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , or a pharmaceutically acceptable salt thereof.

48. The compound for use of claim 42 or the use of claim 42, wherein the compound is represented by the formula: [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof.

49. The compound for use of claim 42 or the use of claim 42, wherein the compound is represented by the formula: [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof.

50. The compound for use of claim 42 or the use of claim 42, wherein the compound is represented by the formula: [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof.

51. The compound for use of claim 42 or the use of claim 42, wherein the compound is represented by the formula: [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof.

52. The compound for use of any one of claims 1 and 4-51, or the use of any one of claims 2-51, wherein the compound is for use with a pharmaceutically acceptable carrier in a pharmaceutical composition.

53. The compound for use of any one of claims 1 and 4-52, or the use of any one of claims 2-52, wherein the birthmark is selected from the group consisting of port-wine stains / capillary malformations, melanocytic nevus, displastic nevi, epidermal nevi, nevus sebaceous, nevus spilus, arterio-venous malformations, lymphatic malformations, and congenital melanocytic nevus.

54. The compound for use of any one of claims 1 and 4-53, or the use of any one of claims 2-53, wherein the birthmark is associated with an activation of phosphorylated extracellular signal-related kinase (p-ERK).

55. The compound for use of any one of claims 1 and 4-54, or the use of any one of claims 2-54, wherein the birthmark is associated with epidermal nevi, nevus sebaceous, nevus spilus, arterio-venous malformations, capillary malformations / port-wine stains, congenital melanocytic nevus, or lymphatic malformations.

56. The compound for use of any one of claims 1 and 4-55, or the use of any one of claims 2-55, wherein the compound is for use topically, subcutaneously, intradermally, or intralesionally.

57. The compound for use of any one of claims 1 and 4-56, or the use of any one of claims 2-56, wherein the compound is for use as a lotion, a spray, an ointment, a cream, a gel, a paste, or a patch.